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Abstract 
One of the critical functions of human adenovirus (hAd) early region 1A (E1A) protein is to 
activate transcription of the early viral genes.  The largest isoform of E1A contains a unique 
region termed conserved region 3 (CR3), which includes a Cysteine-4 (C4) zinc finger 
domain.  This region activates viral gene expression by interacting with and recruiting 
cellular transcription machinery to the regulatory regions of early viral genes.  Although this 
process has been studied at length with hAd type 5 E1A, far less is known about how the 
E1A proteins from other hAd types activate transcription.  There are dramatic differences in 
the potency of transactivation by E1A CR3s from representative hAd species that cannot be 
explained by the current model of E1A transactivation.  I hypothesized that many of the co-
activators targeted by hAd E1A CR3 are conserved between types.  However, I also 
hypothesized that additional cellular factors specific to certain hAd E1A CR3s are also 
required.   The cellular co-activators required by hAd5 E1A CR3 to activate transcription 
were demonstrated to be conserved among representative members of each hAd species.  
Furthermore, the cellular lysine acetyl transferase (KAT) GCN5 was identified as a novel 
negative regulator of E1A CR3 transactivation.  The KAT activity of GCN5 was required to 
exert the effect on E1A CR3.  Finally, the C4 zinc finger domain of CR3 is predicted to differ 
from the rest of E1A by exhibiting a stable structure that is critical for transactivation.  A 
well defined stable solution structure of E1A CR3 was confirmed by NMR spectroscopy.  
Coordination of a single zinc ion was critical to CR3 structure and folding.  Together these 
observations expand the existing model of E1A CR3 transactivation to not only include 
representative members of each hAd species, but also implicate a layer of negative regulation 
and provide structural insight into this paradigm of non-acidic viral transactivators. 
Keywords 
Human adenovirus, E1A, Conserved Region 3, transactivation, transcriptional control, 
protein-protein interactions, C4 zinc finger, TBP, MED23, p300/CBP, SUG1, GCN5 
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Chapter 1  
1 Introduction 
 
1.1 General Introduction 
Viruses are obligate intracellular parasites—they must commandeer cellular processes in 
order to replicate.  All viruses must dismantle host cell defenses and hijack the cellular 
translation machinery during their replication cycle.  Despite a sinister reputation as the 
etiological agents of many—even pandemic—diseases, virus‘ intimate interaction with 
their respective host cells make them invaluable and discriminating biochemical tools to 
dissect and understand cellular processes.  Studies of viral genes have led to landmark 
discoveries in many fields of biology.  Some notable examples include, the first T-cell 
epitope mapped and sequenced, which was the immunodominant T-cell epitope for the 
vesciular stomatitis virus nucleocapsid protein (144), as well as the process of mRNA 
splicing, which was first observed and described using viral mRNA from adenovirus 
infected cells (8).  Clearly, hAd as a tool is no exception, but it is the early region 1A 
(E1A) gene of hAd that has had a tremendous impact on our understanding of cellular 
processes including, but not limited to,  transcription and cell cycle control.  E1A is the 
topic of this thesis and has served as a molecular compass leading the way to a better 
understanding of key cellular regulatory processes.  
1.2 Adenoviruses 
1.2.1 Origins of Adenoviruses 
Adenovirus was first discovered in the early 1950s by two distinct groups on the hunt for 
the causative agent of respiratory infections.  In 1953, Rowe and colleagues observed 
unexpected death of primary human adenoid tissue that was the result of pre-existing 
virus present in the isolated tissues (122).  One year later in 1953, while studying 
respiratory disease in army recruits, Hillman and Werner were able to induce cytopathic 
effects (CPE) in human cells with respiratory secretions from infected patients (65).  In 
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1956, this new class of infectious agents was collectively called adenoviruses, after the 
tissue the prototype strain was originally isolated from.  Although this virus turned out to 
be a major causative agent in outbreaks of respiratory disease among military recruits that 
Hillman and Werner were studying, adenovirus was not the etiological agent of the 
common cold that both groups set out to find. 
Nearly ten years later in 1962, a seminal discovery by Trentin and colleagues re-ignited 
interest in adenoviruses.  Injection of hAd type 12 (hAd12) into newborn baby hamsters, 
and later baboon retinas, induced malignant tumors.  This marked the first human virus to 
cause cancer (100, 141).  However, not all hAds can cause cancer in rodents. This 
property was originally used to help classify members of the hAd family into subgroups, 
now referred to as species.  As a specific example, hAd5 and other members of species C 
do not induce tumors when injected into immunocompetent rodents (126).  However, all 
hAds are capable of transforming rodent cells in culture (44, 45, 93, 126).  Since the 
landmark observation that hAds could induce cancer, they have been used as tools to 
intensively study subversion of normal cell functions in an attempt to decipher the 
barriers that normally protect cells from aberrant growth.  To date, hAds have never been 
shown to cause cancer in humans. 
1.2.2 Taxonomy of Adenoviruses 
Adenoviruses belong to the family Adenoviridae, which includes well over 100 members, 
and consist of five genera: Aviadenovirus, Siadenovirus, Atadenovirus, Ichtadenovirus 
and Mastadenovirus.  The Mastadenoviruses include members that infect many species 
of mammals, but adenoviruses seldom if ever, cross species barriers; for example, human 
adenovirus is unable to replicate in murine cells and vice versa .  Members of this family 
are icosehedral viral particles ranging in size from 60-90 nm in diameter, and all contain 
a linear double stranded DNA genome, which in the case of hAd5 is approximately 36 
kilobase pairs (kbp) in size (126).  There are currently more than 52 serotypes (soon to be 
called types, because serology is no longer used to distinguish one adenovirus from 
another) of hAd that are further grouped into six species, A-F, based on a series of 
biological properties including oncogenic potential (Table 1-1).  These species of hAd 
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All 52 serotypes of hAd have been classified into six subgroups based on the criteria 
shown.  The prototypical hAd, hAd5 of subgroup C has been the subject of the vast 
majority of study to date.  Adapted from (126). 
Table 1-1:  The classification of the different human adenovirus serotypes into six 
speciess. 
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are also quite similar at the molecular level, and in the case of E1A and hexon sequence, 
the original classification into species remains unchanged. 
1.2.3 Epidemiology of Adenoviruses 
Adenoviruses are ubiquitous in the environment.  All humans will have been infected by 
at least one hAd type in their lifetime.  Although initially thought to be linked only to 
mild disease in humans, more recently emerging hAd strains have been associated with 
more serious pathogenesis.  Recent studies have implicated latent adenovirus infections 
as co-factors in the development of chronic obstructive pulmonary disease (COPD) (62, 
106).  According to the National Institute of Health, COPD was the fourth leading cause 
of death in the United States in 2010 (102).  Perhaps more startling was the recent 
emergence of hAd type 14A, a new variant of hAd14 that caused severe pneumonia and 
resulted in the hospitalization and death of individuals with otherwise healthy immune 
systems (90). 
1.2.4 Physical Properties of Adenoviruses 
Adenoviruses are non-enveloped viral particles consisting of a linear double stranded 
DNA genome housed in an icosehedral protein shell or capsid.  Each viral capsid consists 
of 252 capsomeric units, of which 240 are hexons and 12 are pentons (52).  Hexons are 
surrounded by six capsomeres, and five capsomeres surround each penton.  The 
protruding fiber protein is attached to a base formed by pentons and varies in length 
among hAd types (104, 105).  The penton base and fiber protein are important for 
attachment and entry of hAd particles into target cells via phagocytosis.  The penton base 
contains an arginine-glycine-aspartic acid or ―RGD‖ motif that mediates attachment and 
entry into a broad range of human cells. Attachment is mediated through an interaction 
with cellular integrins, such as αvβ3 and αvβ5 and is commonly referred to as fiber-
independent entry (154).  hAd is also capable of receptor-mediated phagocytic entry 
through the fiber protein.  In the case of hAd5, the receptor is the coxsackie and 
adenovirus receptor (CAR), which is commonly found on the surface of epithelial cells 
(94). 
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All hAds posses a linear double stranded genome ranging in size from 30-38 kbp with a 
conserved organization.  The genome has inverted terminal repeats (ITRs) at both ends 
and is capped with a 55 kilodalton (kDa) terminal protein covalently attached to the 5‘ 
ends of each strand through a phosphodiester bond between the terminal viral nucleotide 
and a conserved serine residue in the terminal protein (119).  The genome is organized 
into nine transcriptional units: early 1A (E1A), 1B (E1B), E2, E3, E4, pIX, virus-
associated RNA (VARNA), U exon and late genes, which are transcribed from both 
strands of the genome (Figure 1-1) (125, 140).  Early genes are defined as those 
expressed before the onset of viral genome replication and late genes are defined as those 
whose expression begins with the onset of viral genome replication (126). The early 
genes are generally responsible for preparing the cell to replicate the viral genome and/or  
directly participate in the replication of the viral genome.  The late transcript codes for 
primarily structural genes.  
1.2.5 The Genes and Life Cycle of Adenoviruses 
As mentioned above, the virus life cycle begins with contact between the virus particle 
and the target cell and internalization by phagocytosis.  The adenovirus particle is then 
uncoated, releasing the viral core, which contains the viral genome, into the cytoplasm 
(89).  The core then traffics to the nucleus, where transcription of the early viral 
transcripts begins (23). 
The first gene expressed from the viral genome is E1A from a constitutively active 
promoter/enhancer element.  E1A is the focus of this thesis, and the details of E1A 
function will be discussed further in later sections.  Briefly, E1A has two critical 
functions in the viral replication cycle:  1) E1A uncouples the host cell cycle driving the 
cell into S-phase to create an intracellular milieu conducive to viral replication and 2) 
activates transcription of the early viral genes, kick-starting the replication cycle (46, 
110).    
The E1 region of the viral genome is composed of E1A and early region 1B (E1B).  In 
hAd5, the E1B region codes for two proteins of 55kDa and 19kDa, referred to as E1B-
55k and E1B 19k, respectively.  The major function of these proteins is to counteract the 
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Cartoon representation of the hAd5 dsDNA genome.  The hAd5 genome has eight 
transcriptional units, five or which are expressed early during infection: E1-4, two are 
expressed delayed early: IX and VARNA, and one late during infection; L. U Exon is 
not depicted, but located between the E3 region and the fiber gene in the late 
transcription unit in the left transcription direction. 
Figure 1-1:  Genome Organization of human Adenoviruses 
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p53 tumor suppressor pathway and block apoptosis that is stimulated by the effects of 
E1A (30).  Early in infection the E1B-55k protein functions as an E3 ubiquitin ligase in 
concert with the cellular ubiquitin-dependent degradation pathway to target p53 for 
degradation, thus inactivating its downstream effects (157).  Later in infection, E1B-55k 
functions in combination with the viral E4 gene product E4ORF6 to export viral mRNA 
from the nucleus to the cytoplasm to facilitate late mRNA translation (54, 55).  The 
smaller E1B product 19K is a Bcl2-homologue that inhibits apoptosis by interacting with 
proteins such as BAK (Bcl2-homologues antagonist/killer) and blocking the release of 
mitochondrial cytochome C (27, 38, 152). 
The E2 region codes for three genes critical for replication of the viral genome.  The 
three genes encoded by the E2 region are the terminal protein (discussed above in section 
1.2.4), the DNA-dependent DNA polymerase required to replicate the genome, and the 
single stranded DNA binding protein, which have molecular weights as mature proteins 
of 55, 140 and 59 kDa, respectively (19-22, 82, 147).  Viral DNA replication occurs from 
the infecting template initially primed by the terminal protein.  The 5‘ phosphate of the 
first nucleotide is covalently attached to the hydroxyl group of a conserved serine residue 
of the terminal protein. Viral DNA replication proceeds in the standard 5‘ to 3‘ direction 
by the viral DNA-dependent DNA polymerase.  As single-stranded intermediates are 
produced by displacement of one strand of the duplex, these intermediates are bound by 
the viral single-stranded DNA binding protein.  Progeny genomes are later capped with 
terminal protein and can then also serve as templates for additional progeny genomes 
(74).  
The E3 region of the adenoviral genome contains genes that code for proteins required 
for evading and modulating the host immune system, thereby protecting the infected cell 
from the immune response.  The 19k E3 glycoprotein is involved down regulating surface 
expression of major histocompatibility complex I (MHCI) on infected cells by disrupting 
endoplasmic reticulum (ER) function (16-18, 80).  Moreover, the E3 10.4 and 14.4kDa 
proteins cooperate to uncouple the Fas signaling pathway from the Fas receptor (FasR) 
(25).  The E3 region is also known as the hypervariable region of the adenovirus genome, 
as this region exhibits the most genomic sequence variability among hAd types.  Based 
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on these characteristics, it was assumed that the newly emerged hAd14A had evolved a 
new ORF in the E3 region that was ultimately responsible for the increased 
pathogenicity.  However, this was not the case; sequencing the entire genome revealed 
only one unique characteristic of hAd14A, a two codon deletion in the fiber gene (67, 
73). 
The final early region activated by E1A is the E4 region, which contains a collection of 
genes with quite diverse functions.  As previously stated, the E4ORF6 gene product in 
conjunction with E1B55k plays a role in viral mRNA export.  The E4ORF6/E1B55k E3 
ligase complex inactivates the Mre11/Rad50/NBS1 (MRN) cellular DNA damage 
response, preventing the viral genome from being recognized and inactivated by non-
homologous end joining (136).  The E4ORF3 gene for a long time was an enigma of hAd 
biology, mainly because the E4ORF3-deleted virus had no detectable phenotype (127).  
The E4ORF3 protein was originally thought to play a role in suppressing cellular 
translation late in infection (128).  Very recently, it was shown that the E4ORF3 protein 
is a redundant mechanism for silencing transcription of p53-stimulated genes by 
heterochromatinization of 265 p53-responsive promoters (132).  This tiny protein of only 
116 amino acids (aa) is capable of very specific transcriptional silencing of a select subset 
of genes that appears to rely in part on the SUV39H1/2 methyltransferases (132).  
E4ORF3 is a shining example of how critical dismantling the p53 pathway is for the viral 
infection cycle; hAd has at least two distinct mechanisms to inactivate the pathway at two 
critical points.  The E4ORF4 gene codes for a protein that functions to inhibit protein 
phosphatase 2A (PP2A), thereby inhibiting the family of protein phosphatases that 
account for the majority of serine/threonine phosphatase activity present in many cells 
(76, 156).  PP2A and E4ORF4 regulate expression of the E4 promoter by 
dephosphorylating E1A to limit production of the toxic gene products of the E4 region, 
thereby preventing premature cell death (151).  This aspect of E4ORF4 function will be 
discussed in detail in later sections dealing with E1A-dependent transactivation. 
The gene products of the viral early transcription units all cooperate to produce a cellular 
environment conducive to viral replication that allows expression of the late genes.  The 
adenoviral late gene region generates multiple transcripts from the major late promoter.  
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The identification of the origin of the multiple late gene transcripts came from an electron 
microscope-based heteroduplex analysis of viral mRNA from infected cells with DNA 
from the late regions of the viral genome.  This revealed multiple DNA loops of various 
sizes (8).  The explanation for these loops ultimately led to the discovery and 
characterization of mRNA splicing in mammalian cells (8).  The late transcripts code for 
the both structural and non-structural proteins involved in viral assembly, packaging and 
egress (126).  These final stages of the viral replication cycle take place in the nucleus. 
Eventually the host cell is lysed, releasing new viral progeny and the virus life cycle 
repeats (126).  
1.3 The Adenovirus E1A Gene and Gene Products 
1.3.1 The Adenovirus E1A Gene and Transcripts 
The adenovirus E1A gene is approximately 1 kb in length and is located at the extreme 
left end of the viral genome downstream of the left ITR (Figure 1-1). E1A is absolutely 
required for productive infection in human cells at low multiplicity of infection (MOI) 
(72). Immediately upon infection, the E1A gene of hAd is expressed.  Indeed, E1A is the 
first viral gene detectable during infection. E1A expression is controlled by a 
constitutively active promoter and duplicated enhancer element (63, 64, 103).  The E1A 
gene contains two short introns that give rise to five spliced products.  The hAd5 E1A 
transcript is alternatively spliced to yield five different isoforms, 13S, 12S, 11S, 10S and 
9S, that were named based on their sedimentation coefficients (Figure 1.2) (126).  The 
largest E1A single-spliced products (13S and 12S) predominate early in infection, and at 
late times in infection the smaller double spliced products (11S, 10S and 9S) are observed 
(114). 
1.3.2 The E1A Proteins 
In hAd5 the 13S, 12S, 11S, 10S and 9S  mRNAs give rise to proteins of 289 residues (R), 
243R, 217R, 171R and 55R respectively (Figure 1-2).  The two largest E1A isoforms are 
identical except for a 46 amino acid (aa) region unique to the 289R E1A isoform (114).  
Both the 289R and 243R isoforms of E1A are phosphorylated and phosphorylated, 
residues in E1A appear to be involved in protein-protein interactions (59, 
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The hAd-5 E1A gene is alternatively spliced to yield 5 mRNA products ranging in size 
from 13S to 9S.  These encode proteins ranging in size from 289 residues (R) to 55R.  
Coding regions are shaded. Note that splicing preserves the translational reading frame 
in all cases except for the 9S encoded 55R product (grey box).  
Figure 1-2:  Splice products of the hAd5 E1A gene. 
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77, 151).  The two largest E1A isoforms localize to both the cytoplasm and the nucleus 
(121, 142).  The remaining three isoforms are produced later in infection, and the precise 
roles of these proteins in the adenovirus life cycle remain elusive (134, 143). 
Early aa sequence alignments of the largest E1A proteins from different hAd types 
revealed three regions of conservation, aptly named conserved regions (CR) 1, 2 and 3, 
separated by regions of less conservation (34, 75, 98, 107, 145).  Analysis of the aa 
sequence of 34 human and simian adenovirus E1As refined the boundaries of these 
conserved regions and also revealed a fourth conserved region, CR4, which is located at 
the C-terminus of E1A (Figure 1-3) (3, 4). The relatively high degree of conservation in 
these regions suggests that common functions of different E1As critical to the viral life 
cycle are mediated by the conserved regions.  
1.3.3 The E1A N-terminus/Conserved Region 1 
In hAd5 the less conserved N-terminal region spans residues 1-41 and the boundaries of 
CR1 are aa‘s 42-72 (4).  To date there are 15 cellular proteins known to interact with the 
41 amino terminal residues of E1A.  The majority of these cellular factors are involved in 
transcription, including activating protein-2 (AP2) (130), thryroid hormone receptor (TR) 
(95, 96, 148), p400 (48), transformation/transcription domain-associated factor (TRRAP) 
(31), p300/CBP associated factor (pCAF) (118), GCN5(81), TATA-binding protein 
(TBP) (86, 131) and most importantly, p300/CREB binding protein (CBP) (2, 35).  The 
interaction of the N-terminus of E1A and p300/CBP is capable of inducing global 
changes in p300/CBP occupancy of almost 70% of cellular promoters in infected cells, 
which ultimately results in a global hypoacetylation of histone H3 lysine 18 (H3K18) (41, 
66).   
Different classes of cellular proteins also interact with the N-terminus of E1A and 
associate E1A with protein degradation and signaling.  The N-terminus of E1A interacts 
with the S8 (SUG1) and S4 components of the 19S proteasome subunit.  This interaction 
intimately links E1A function to alterations in the regulated turnover of individual E1A 
molecules and its cellular targets (57, 117, 142).  The N-terminus of E1A also interacts 
with a series of cellular proteins that feed into protein-protein signaling networks.  These 
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Figure 1-3:  Alignment of the E1A proteins of hAd. 
The sequences of one representative E1A protein from each of the six hAd subgroups 
were aligned and shaded for conservation.  Darker shading corresponds to higher levels 
of conservation.  Gaps are indicated as dots.  The positions of the CRs are indicated as 
solid bars.  Adapted from Avvakumov et al. 2004. 
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include the Ran GTPase (29), the protein kinases Nek9 (113) and protein kinase A 
(PKA), via the RIIα subunit (40).  These signal transduction proteins interact with 
conserved elements of the N-terminus of E1A.  Upon examination of this  impressive list 
of cellular factors that interact with the first 41 residues of E1A, the model of how E1A 
facilitates such diverse functions of transformation, S phase induction and transcriptional 
activation/repression begins to take shape (9, 42, 49).  However, the complexity and 
sheer number of these interactions begs the question, how does E1A bind and organize 
these factors? 
Two independent studies took on the painstaking task of systematically mutating the first 
30 residues of hAd5 E1A and subsequently assessing the binding of factors to each 
mutant (12, 116).  For the most part, one or two residues are critical for the interaction of 
each of the known cellular factors with the N-terminus of E1A.  However, three residues, 
L19, L20, and L23, were shown to be critical to the interaction with a large number of 
cellular binding partners. The N-terminus of E1A is predicted to form an amphipathic 
alpha helix from residues 10-27, which likely allows for spatial organization and 
interaction with the large number of diverse cellular proteins shown to interact within this 
region (110). 
CR1 cooperates with the N-terminus in binding several common cellular targets 
including p300/CBP and TRRAP (32, 36, 133, 155).  CR1 also cooperates with CR2 in 
binding to the pRb tumor suppressor and family members.  The CR1 interaction with pRb 
is via the E2F binding site of pRb. Although considered a low affinity interaction relative 
to high-affinity interaction site in CR2, CR1 is critical to dissociating pRb from E2F 
transcription factors, thereby facilitating expression of not only S-phase genes but also 
the viral E2 transcription unit (39, 69).  It should be noted that the cellular E2F 
transcription factor family owes its name to the adenoviral E2 transcription unit, where 
the consequences of pRb loss were first studied (78) Change SHENK for KOVESDI 
1986.   
As a direct result of the diverse interactions of the N-terminus and CR1 of E1A with 
cellular proteins, they are both essential to E1A-dependent transformation of rodent cells 
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in culture (7).  These two regions of E1A also constitute a transcriptional activation 
domain when fused to a heterologous DNA-binding domain (DBD) (11).  Based on the 
transcriptional nature of many of the binding partners of the N-terminus/CR1 and the 
relative high-affinity of these interactions, this observation is not at all surprising. This 
same region is also capable of functioning as a generalized transcriptional repressor by 
sequestering limiting factors, such as p300/CBP (7, 112).  In the context of viral infection 
however, the N-terminus/CR1 of E1A cannot interact with the viral early promoters on its 
own and is therefore not thought to be sufficient to stimulate transcription of any viral 
genes. 
1.3.4 The E1A Conserved Region 2 
CR2 of E1A is perhaps the most well studied region of E1A in terms of transformation 
and subversion of cellular tumor suppressor gene products.  CR2 spans residues 115-137 
and includes the DLXCXE motif (corresponding to residues 121-126 in hAd5) that 
confers high-affinity interaction with pRb (4).  This interaction between E1A (CR2) and 
pRb constituted the first demonstration of a physical interaction between an oncoprotein 
and a tumor suppressor protein (108).  CR2 is required to facilitate efficient and 
productive infection by providing two functions.  Firstly, E1A CR2 forces quiescent cells 
into S-phase. Secondly, E1A CR2 indirectly activates the viral E2 transcription unit. Both 
of these functions are mediated through interaction with pRb and family members (6, 
115). 
Since this landmark role for CR2 was described, additional functions related to cellular 
transformation have been attributed to this region of E1A.  CR2 has additional roles in 
oncogenic transformation of rodent cells independent of pRb (71, 79, 85, 99, 124, 146, 
153), induction of apoptosis and sensitization of cells to tumor necrosis factor (101, 129) 
as well as stabilization of p53 (162).  These pRb-independent functions of CR2 are likely 
the result of interaction with the three other cellular proteins known to bind this region: 
BS69, UBC9 and the S2 component of the 19S proteasome (61, 142, 159). 
The cellular protein BS69 was originally identified as a 69 kDa protein that was 
immunoprecipitated with E1A (61).  BS69 was shown to interact with E1A via a PXLXP 
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motif within CR2 (residues 112-117 in hAd5) that interacted with the MYND domain of 
BS69, also known as ZYMD11 (1).  Interestingly, this PXLXP motif is only found in 
species A and C hAds (4).  BS69 was demonstrated to have a repressive effect on E1A 
transactivation (61).  How BS69 functions as a repressor and what role it plays in E1A-
mediated oncogenic transformation is still unclear; however, BS69 is clearly involved in 
cell cycle control and senescence (68, 109, 161). 
CR2 also interacts with the small ubiquitin-like moiety (SUMO) conjugase ubiquitin 
conjugase 9 (UBC9) via an EVIDLT motif corresponding to residues 118-123 in hAd5.  
The E residue of this motif actually overlaps with the DLXCXE pRb binding motif of 
CR2, again highlighting the complexity of E1A interactions with cellular proteins (4, 
159).  The EVIDLT interaction motif in CR2 contacts the surface of UBC9, which can 
normally interact non-covalently with SUMO-1.  The interaction of E1A with UBC9 
displaces SUMO-1 from the N-terminus of UBC9. In this manner E1A effectively blocks 
SUMO chain formation, which requires the non-covalent interaction between SUMO and 
UBC9 (159). 
Finally, CR2 also interacts with the S2 component of the 19S regulatory subunit of the 
26S proteasome.  This interaction maps to residues 124-147 and also overlaps the pRb 
binding motif (4, 162).  CR2 effectively stabilizes p53 and sensitizes cells to tumor 
necrosis factor alpha (TNF-α) by interacting with S2 and blocking degradation of p53 
(142). 
1.3.5 The E1A Conserved Region 3 
Conserved region 3 is the major focus of this thesis.  The sequence and function of E1A 
CR3 is discussed in detail in section 1.4. 
1.3.6 The E1A Conserved Region 4 
Exon two is the final frontier of E1A biology. Despite 20 years of extensive study, very 
little is known about the function and cellular targets of the product encoded by the 
second exon of E1A (4, 46, 110). Conserved region 4 (CR4) lies within exon 2 of E1A, 
and in hAd5, CR4 spans residues 240-288 (4).  The region now identified as CR4 has a 
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long and bizarre history in saga of E1A-induced oncogenesis.  CR4 is required for 
transformation in combination with E1B (33, 138, 158), but curiously inhibits 
transformation in cooperation with activated ras (13, 139).  This region also plays a 
major role in E1A‘s ability to promote cells to undergo mesenchymal to epithelial 
transition (MET). This so called tumor suppressor function of E1A, is mediated by 
activating transcription of epithelial specific genes (58, 123).  
Given the track record of E1A, it is of no surprise that these paradoxical functions are 
linked to interaction with an eclectic but short list of cellular targets. The first and best 
characterized target of CR4 is C-terminal binding protein (CtBP).  It was first discovered 
as an E1A-interacting protein and so named because it is the protein that co-precipitated 
with the C-terminus of E1A (123).  The sequence PXDLS is the motif that confers 
interaction with CtBP.  It is present in all known E1A sequences and is also found in 
cellular proteins that interact with CtBP (4, 110, 123).  CtBP is a cellular factor that 
functions in cells as a transcriptional co-repressor.  CtBP interacts with a series of 
promoter-bound transcription factors and recruits repressive chromatin remodeling 
complexes to shut off transcription (26).  Through its interaction with CtBP, E1A can 
alter cellular gene expression by two distinct mechanisms that require different isoforms 
of E1A.  First, either 12S or 13S E1A can sequester CtBP through the PXDLS motif, 
effectively de-repressing promoters that require CtBP to remain repressed (26).  Since 
this model was proposed, a second interaction site for CtBP was identified in CR3 of 
E1A.  The 13S E1A product is capable of interacting with CtBP at repressed promoters. 
Using the potent transactivation domain of CR3, 13S E1A can directly activate CtBP-
silenced promoters (15).  Therefore the interaction with CtBP alone is capable of having 
paradoxical effects on cellular transcription, only adding to the complexity of E1A exon 2 
function. 
Exon 2 of E1A also interacts with DYRK1A/1B family of dual specificity kinases, and 
this interaction maps to residues 239-278 of CR4 (4, 158, 163).  This interaction is 
conserved across all six hAd speciess as are the two arginine residues (R262/R263) 
required for this interaction (4, 158).  E1A activates the kinase activity of DYRK1A, 
resulting in increased phosphorylation of DYRK1A targets including histone H3 and the 
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transcription factor GLI1 (158, 163).  The consequence of increased DYRK kinase 
activity is increased GLI-dependent transcription and dramatically decreased 
transformation by E1A in cooperation with E1B.  Both of these consequences are not 
only E1A-dependent, but also require the double arginine binding site found within CR4 
(158). 
Recently the Forkhead transcription factors FOXK1 and FOXK2 were identified as new 
targets of E1A exon 2 (77).  These transcription factors interact with E1A through S219 
(S174 in 12S E1A) in a phosphorylation dependent manner and appear to inhibit E1A 
transformation in cooperation with activated ras (77).  Clearly, our understanding of the 
biology of E1A exon 2/CR4 has identified its involvement in multiple functions of E1A 
including transcriptional control, the precise role for this region in E1A function is 
continually evolving. 
1.3.7 E1A as a Viral Hub Protein 
The model by which E1A performs its functions is a fascinating example of viral 
subversion of host cell factors.  E1A has no DNA binding or enzymatic activities (5, 24, 
164).  Instead E1A interacts with cellular factors and either modulates or relocalizes their 
function.  This model of cellular subversion related to the high density of sequence 
conservation in E1A.  The residues that are required to interact with key cellular 
regulators are in general quite conserved across hAd families.  After extensive mutational 
analysis of E1A, it became clear that E1A can tolerate small and large deletions in one 
region that do not affect the function of adjacent regions (83, 85, 99, 120, 160).  
Moreover, small fragments of E1A can retain their function when expressed on their own 
(159). Given these properties of E1A function, much of the E1A protein can be thought 
of as a series of protein-protein interaction motifs, some of which are capable of 
interacting with multiple targets (110). 
1.4 The Model of E1A-Dependent Transactivation 
E1A function can be subdivided into two roles critical to the viral replication cycle.  E1A 
drives the infected host cell into S-phase of the cell division cycle, thus providing an 
optimal environment for viral DNA replication.  This function of E1A does not require 
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the unique 46 amino acid region within CR3, and thus the 12S E1A product (243R in 
hAd5) is sufficient to perform this role during infection (46, 110).  Perhaps equally 
important, the E1A protein is required to activate transcription of the early viral genes 
and thus initiate the viral replication cycle (9, 46).  Nearly 25 years ago, this function of 
E1A was shown to absolutely require the largest E1A isoform, which includes CR3 (10, 
60).  As a specific example, host range in hAd was originally based on the ratio of virus 
growth in 293 cells versus HeLa cells.  Two classes of mutants were isolated that grew on 
293 cells, but failed to grow efficiently (3.5-4 log reduction) on HeLa cells, and these 
mutants were termed host-range mutants (hr) (60).  Group II hr mutants were able to 
grow on other tumor cell lines, and the mutations mapped to E1B.  Group I hr mutants 
failed to synthesize early viral mRNAs in HeLa cells.  All group I hr mutants not only 
mapped to E1A but all of them are single point mutants within CR3.  Synthesis of viral 
early mRNAs could be rescued in 293 cells where E1A is supplied in trans (10, 47, 53, 
56).  Therefore the largest E1A protein which contains CR3 was responsible for early 
viral mRNA synthesis. 
E1A CR3 encodes a four cycteine (C4) zinc finger domain (Culp 1988) and functions as 
a potent transcriptional activation domain that is critical for activating early viral gene 
expression (7, 9, 28, 43, 49). CR3 alone is sufficient to potently activate transcription 
when tethered to a promoter as a fusion to a heterologous DBD (84, 91).  Overlapping 
deletion mutants across the entire E1A coding region were used to deduce sub-regions of 
CR3 that are required for function.  Virtually all deletion mutants within CR3, unlike 
other regions of E1A, fail to activate transcription, and no short linear interaction motifs 
(SLIMs) have been identified within this region (37, 70, 110). Furthermore, the CR3s 
from the six representative hAd E1A proteins are predicted to have a defined structure 
(110).  Taken together, these findings reinforce the concept that CR3 is a more ordered 
region of E1A, and that this structure is required to activate transcription. However, a 
three-dimensional structure has yet to be defined for CR3. 
Studies of CR3 required a change in tactics from the use of large deletion mutants. 
Instead, the current model of CR3 function was built from painstaking analysis of point 
mutants. Indeed, every residue of hAd5 CR3 has been mutated to at least a conservative 
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aa and assayed for transcriptional activation (51). This effort eventually defined the 
factors and the key interaction residues of CR3 that are required to activate transcription 
of the early viral genes and generated a model that serves as the paradigm for non-acidic 
viral transcriptional activators.  In hAd5 E1A, CR3 spans residues 144 to 191 and is 
comprised of three functional subdomains: an N-terminal zinc binding region mapping 
between residues 144 and 179, a C-terminal promoter targeting region spanning residues 
183 to 188, and an acidic region that extends beyond CR3 and spans residues 189 to 200, 
termed auxiliary region 1 (AR1) (Figure 1.4) (4, 87, 137, 149). Deletion of the entire C4 
zinc binding subdomain (aa 144-179), or any portion of it, results in a complete loss of 
transcriptional activation function (37, 70). However, mutation of the promoter targeting 
domain leads to a dominant-negative phenotype.  Mutants in the promoter-targeting 
subdomain continue to bind to limiting cellular factors through the zinc finger 
subdomain, but are unable to associate with a promoter, resulting in sequestration of 
limiting cellular factors (squelching) and a loss of activation by wild-type E1A (149).  
Deletion of AR1, or a decrease in its overall acidic charge, also results in a loss of 
transcriptional activation (137).   
The zinc finger subdomain of CR3 interacts with cellular TBP and MED23 (a component 
of the mediator adaptor complex) in order to nucleate the transcriptional preinitiation 
complex. These two targets interact with specific residues found within the zinc finger 
subdomain (Figure 1-4) (14, 51, 135, 149). Furthermore, these interactions require 
specific zinc coordination, because a single point mutant in CR3 that converts the zinc 
finger to a C2H2 type results in a complete loss of transcription activation and binding 
(150). E1A has no specific DNA binding activity and is recruited to viral and cellular 
promoters via interaction between the promoter targeting subdomain of E1A CR3 
spanning residues 183 to 188 in hAd5 and cellular sequence-specific DNA binding 
transcription factors (87, 88, 149). The adenoviral early region promoters contain binding 
sites for many cellular transcription factors that interact with this short region of CR3, 
including those of the cyclic AMP response element/activating transcription factor (ATF) 
family, upstream stimulatory transcription factor (USF), and Sp1 (87, 88). This region 
has also been shown to bind TBP-associated factor II 250 (TAFII250) and TAFII 135 
(50, 92). Interestingly, the promoter-targeting region in E1A is predicted to be 
20 
 
Top:  A linear representation of hAd5 289R E1A, conserved regions are labeled and 
AR1 is denoted in yellow.  Bottom:  The residues of E1A Cr3 from 139-200 are shown 
using one letter code.  The coordinating Cysteines are circled and the key targets of 
CR3, TBP, MED23 and ATFs,are shown in green, blue and red respectively.  The key 
residues interacting with each target are indicated by the corresponding color.  The 
boundaries of the residues of CR3 known to be required for interaction with APIS 
(residues 169-188) and 20S proteosome (residues 161-177) and pCAF (residues 139-
147)  are marked by #, * and ^ respectively. 
Figure 1-4:  The Current Model of E1A Conserved Region 3 Transactivation. 
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unstructured, and the disordered nature of this region of CR3 may contribute to its ability 
to interact with multiple unrelated transcription factors (110). AR1, which in hAd5 E1A 
is a series of six repeats of glutamic acid and proline (EP), is consistently predicted to be 
structurally disordered (110). The target(s) of AR1 remain to be identified, but it is 
known that the overall negative charge is critical to its function, whereas glycine can 
substitute for the prolines without a loss of function (137).  
At the time I began this project, there existed a model for assembly of an active 
transcription pre-initiation complex by CR3.  E1A CR3 orchestrates the nucleation of 
multiple key transcriptional regulators via distinct subdomains.  E1A is recruited to the 
viral DNA template via interaction with sequence-specific DNA binding transcription 
factors through the promoter targeting subdomain, whereas TBP and MED23 are 
recruited via the zinc finger subdomain. Recruitment of these cellular proteins to a viral 
promoter is sufficient to stimulate transcription (9).  E1A CR3 appears to be an example 
where an ordered region, required for specific interaction with a few targets (TBP and 
MED23), is juxtaposed to a disordered region required for promiscuous interaction with 
multiple promoter targeting transcription factors (110). The result is a compact, yet 
potent, activation domain capable of activating multiple promoter regions (Figure 1-4). 
Since this model was put forth, multiple additional cellular targets have been implicated 
in CR3-dependent activation of transcription.  More recently, components of both major 
subunits of the proteasome were shown to interact with CR3 of the E1A proteins of each 
of the six hAd species (117). The S8 component of the 19S ATPase proteins independent 
of 20S (APIS) complex interacts with hAd5 E1A CR3 via residues 169 to 188 (Figure 1-
4). The addition of small amounts of exogenous S8 increases CR3 activity, whereas high 
levels abrogate transcriptional activation, suggesting that S8 is required in stoichiometric 
amounts for function. Moreover, small interfering RNA (siRNA) knockdown of S8 
results in a loss of CR3-dependent transcriptional activation at levels similar to those seen 
with siRNA knockdown of other targets of CR3, such as TBP (117). The 20S proteasome 
subunit has also been shown to interact with CR3 independently of APIS and the 26S 
proteasome via residues 161 to 177 of hAd5 E1A (Figure 1.4) (117). Chromatin 
immunoprecipitation experiments show that these proteasome components and E1A are 
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found at both promoter and transcribed sequences, suggesting a role in both transcription 
initiation and elongation. Chemical inhibition of the proteasome represses CR3-
dependent activation of transcription (117). These findings suggest that the proteasome 
directly controls E1A-dependent transcriptional activation. Moreover, mutational analysis 
has also established that the potency of E1A activation is inversely related to stability of 
the E1A protein, similar to other transcriptional activators, including herpes simplex virus 
type 1 VP16 (97, 117). These results suggest that degradation of E1A, and potentially 
other locally associated chromatin bound factors, is required to promote subsequent 
rounds of transcriptional initiation and contributes to the potency of transcriptional 
activation by CR3. 
Recently three additional cellular transcription factors, previously known to interact with 
other regions of E1A, have been demonstrated to have an additional interaction site 
within E1A CR3 and to affect its ability to activate transcription.  The cellular co-
repressor CtBP interacts with E1A at the extreme C-terminus via the PXDLS motif, and 
at a second interaction site in CR3 through residues 161-167 (15, 123).  This interaction 
appears to allow the largest E1A product (289R in hAd5) to activate CtBP-repressed 
promoters, by locally tethering the potent transcriptional activation domain of CR3 to an 
otherwise inactive promoter (15).   
The other two cellular factors recently shown to interact with CR3 are both lysine acetyl-
transferases (KATs) and function as co-activators of E1A CR3 transactivation.  Both 
p300/CBP and pCAF have interaction sites in the N-terminus of E1A (as described in 
section 1.3.3) and were shown by our group to have a second interaction site in CR3  
(111, 112, 116, 118).  The interaction site for pCAF was mapped to residues 139-147, at 
the extreme N-terminal portion of CR3, which is predicted to be outside of the zinc finger 
binding sub-domain (111).  Only a subset of E1As from different hAd species (species B, 
C, D and F) possess this second interaction site for pCAF within CR3, which correlates 
with the ability of pCAF to function as a co-activator of transactivation by these CR3s 
(111).  Although p300/CBP is a critical co-activator of E1A-CR3, the second interaction 
site in CR3 has only been shown for hAd5 E1A and, the exact region of CR3 that 
mediates this interaction remains elusive (112). 
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1.5 Thesis Overview 
The work presented in this thesis is a combination of hypothesis-driven and curiosity-
motivated research.  E1A provided me the luxury of drawing on the vast collection of 
literature with respect to E1A transactivation to form my hypotheses and expand our 
knowledge of this field, while generating exciting and unexpected results that I chose to 
follow up.  
1.5.1 Rationale, Hypothesis and Experimental Approach 
Although a model for CR3-dependent activation of early viral gene expression has been 
proposed, the vast majority of this model was worked out with the one prototypical 
member of the hAd family, hAd5 of species C.  The contributions from Dr. J. Mymryk‘s 
laboratory have painstakingly tried to include other E1As wherever possible, but the fact 
remains that the current model is based largely on hAd5 E1A CR3.  Moreover, since the 
original model was put forth over 10 years ago, multiple additional factors have been 
identified and implicated in regulating E1A CR3 transactivation.  I hypothesized that the 
model for E1A CR3 is far from complete and that non-prototypical E1A-CR3s may have 
unique/alternative means to stimulate transcription from their respective promoters.  My 
approach to elucidating a unifying model of E1A-CR3 transactivation involves expanding 
the existing model of E1A transactivation to representative members of each hAd 
species.  I have chosen a representative member of each species, hAd12 (species A), 
hAd3 (species B), hAd5 (species C), hAd9 (species D), hAd4 (species E) and hAd40 
(species F) as our reference panel of E1As/CR3s based on availability of reagents and 
presence in the literature.  I have endeavored to break new ground with hAd5 E1A CR3 
and extend my findings in the context of the whole hAd family. E1A from hAd5 has 
taught us a great deal about the regulation of cellular processes, and I believe the lessons 
learned from the hAd family as whole will provide entirely new insight. 
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1.5.2 Chapter 2:  Comparison of E1A CR3-Dependent 
Transcriptional Activation across Six Different Human 
Adenovirus Species 
This study constitutes the first systematic analysis of the cellular factors required by six 
different hAd E1A CR3s to activate transcription.  First and foremost, there are dramatic 
differences in how the CR3 regions from six E1As representing each hAd species 
activate transcription as Gal4 DBD fusions.  These differences are conserved across a 
panel of human cancer cell lines and also in MEFs, and cannot be explained by the 
existing model of E1A CR3 function.  The interactions with all of the known co-
activators of E1A CR3 were tested with the panel of representative CR3s, and the 
interaction with MED23, TBP, SUG1 and p300 were shown to be conserved across all 
six hAd speciess.  Moreover, each of these conserved cellular factors was depleted from 
cells and the effect on E1A-CR3 transactivation was determined.  Importantly, the role 
played by each cellular factor was conserved across the entire hAd family.  In order to 
determine if the differences among CR3s for activating transcription were due to 
additional cellular factors, the ability of each CR3 to squelch transcriptional activation by 
hAd5 CR3 was determined.  The competition assay showed conclusively that all six 
CR3s compete for the same limiting factor(s) and surprisingly, that the potency of 
transactivation did not correlate with potency of squelching.  The squelching assay also 
demonstrated that there are additional cellular factors required by E1A-CR3 and that at 
least one is limiting.  Therefore, this series of experiments expanded the existing model 
of E1A-CR3 transactivation and showed us that the model is not yet complete. 
1.5.3 Chapter 3:  Cellular GCN5 is a Novel Regulator of E1A-CR3 
Transactivation 
The Mymryk Laboratory has published the identification of a second pCAF binding site 
within CR3 of E1A, however this interaction was not conserved among all speciess of 
hAd.  I hypothesized that those species of hAd that did not bind pCAF through CR3 
could be targeting the closely related KAT GCN5.  Furthermore, the Mymryk laboratory 
previously identified an interaction between CR3 of E1A and yeast GCN5.  GCN5 had 
also been shown previously to interact with the N-terminus E1A.  In this study a second 
interaction site for GCN5 within CR3 of E1A was identified and mapped to residues 178-
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184.  This interaction through CR3 was conserved across all six hAd species and 
independent of the pCAF interaction, which binds CR3 through residues 139-147.  GCN5 
is a negative regulator of E1A CR3 transactivation, as depletion of GCN5 by RNAi 
results in an increase in E1A CR3 transactivation.  Furthermore, overexpression of 
exogenous GCN5 decreases CR3 transactivation and also transactivation by full length 
E1A.  GCN5 is recruited to the viral E4 promoter in an E1A dependent manner and 
requires both interaction sites in E1A for proper recruitment.  This is the first 
demonstration of the cooperative recruitment of a cellular factor to a promoter through 
different regions of E1A and this is likely a recurring theme for many of the cellular 
factors that interact with multiple regions of E1A.  It is the KAT activity of GCN5 that is 
responsible for the negative effect on E1A-CR3 function, as E1A dependent 
transactivation increases in hat/hat MEFs, where both endogenous copies of GCN5 have 
point mutations in the active site abrogating KAT activity.  In addition, E1A dependent 
transactivation also increases when cells are treated with a specific inhibitor of GCN5 
KAT activity.  Virus yield is diminished in the presence of the inhibitor, suggesting that 
an ideal and balanced level of E1A transactivation is required for optimal virus 
replication.  I have therefore identified GCN5 as a novel negative regulator of E1A 
dependent transactivation. 
1.5.4 Chapter 4:  The Structure of E1A CR3 
There is currently no structural model of the C4 zinc finger subdomain of E1A-CR3.  
Unlike the rest of E1A which contains SLIMs, CR3 is completely devoid of these motifs.  
In addition, CR3 does not tolerate deletions without total loss of function, suggesting this 
region may in fact be structured.  In silico predictions of order versus disorder in E1A 
reveal a potential ordered, or structured domain that corresponds to the zinc finger 
subdomain of CR3.  I undertook the task of generating a 3D structure of E1A CR3 by 
NMR spectroscopy.  E1A CR3 residues 139-204 was overexpressed in E. coli and 
purified. The purified CR3 was of correct mass and could compete for MED23 binding.  
CR3 was labeled with 
15
N and a 2D Heteronuclear Single Quantum Correlation (HSQC) 
spectrum was obtained which demonstrated that CR3 was structured.  There was however 
a very flexible region that obscured several peaks.  AR1 was removed from CR3 and a 
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new 2D HSQC spectrum was collected that again showed CR3 was structured, but the 
spectra was without sufficient resolution to eventually yield a structure.  Further analysis 
showed that the structure of CR3 was zinc dependent as chelation of zinc with EDTA 
abolished the structured CR3 signature.  Mass spec analysis revealed that CR3 residues 
139-190 bound a single zinc ion, however this experiment also revealed a smaller peptide 
corresponding to residues 139-182, which is most likely the result of proteolytic cleavage 
which also bound a single zinc ion.  To avoid the complications of two species in the 
structural determination, an even smaller fragment of E1A residues 139-178 was selected 
for further study.  This region would avoid proteolytic cleavage and also removes a non-
coordinating cysteine residue that could complicate the analysis.  A reliable 3D structure 
of the zinc finger subdomain of CR3 has not yet been determined.  With structural 
information about the orientation of residues within CR3, a highly detailed model of 
E1A-CR3 transactivation can be generated. 
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Chapter 2  
2 Comparison of E1A CR3 Dependent Transcriptional 
Activation Across Six Different Human Adenovirus 
Species 
2.1 Introduction 
The adenovirus (AdV) E1A oncoprotein is the first gene expressed upon infection and 
performs two essential roles in order to initiate the viral replication cycle.  E1A 
uncouples the cell cycle control program of the host cell, driving it into S-phase to 
provide an optimal cellular environment for viral replication. This function can be carried 
out by the smaller major E1A isoform (243 residues in hAd5 E1A) (11, 25).  The other 
function of E1A is to activate transcription of the early viral promoters and is mediated 
predominantly by the largest E1A isoforms (4, 18, 23, 24).  The largest E1A isoform, 
coding for 289 residues in hAd5 E1A, differs only from the smaller isoform by a unique 
46 amino-acid C4 zinc finger domain within conserved region 3 (CR3), which is essential 
for viral transactivation (4, 18).  Single point mutations in CR3 were originally isolated as 
hAd mutants with a host range limited to HEK 293 cells, which supply wt E1A in trans. 
These ―host-range‖ mutations render E1A unable to transactivate viral promoters, thus 
preventing virus growth in cells at low multiplicity of infection (MOI), unless wt E1A is 
supplied in trans (13, 16). 
Transactivation by E1A CR3 has been studied predominantly with hAd5, and this has led 
to the establishment of a model for CR3 function.  The region of hAd5 E1A spanning 
residues 139-204 (which includes CR3) is critical for activating transcription necessary 
for virus growth and sufficient for potent activation of a minimal Gal4-responsive 
promoter, as a Gal4-DBD fusion (17, 30).  This 65 aa region of E1A CR3 can be further 
subdivided into the three following subdomains:  an N-terminal zinc finger, a promoter 
targeting region and a region known as Auxiliary Region 1 (AR1) (9, 20, 32).  The 
current model is that the N-terminal zinc finger domain of E1A CR3 activates 
transcription by interacting with cellular TBP and MED23 proteins (6, 19, 31).  The 
Mediator component MED23 is absolutely critical to E1A CR3 function as CR3 fails to 
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activate transcription in MED23 null MEFs (31). Furthermore, this requirement is likely 
shared between the E1A proteins of even very divergent AdVs as mouse adenovirus type 
1 is unable to replicate efficiently in MED23 null MEFs (10).  In order to nucleate a 
functional transcription initiation complex at the early viral promoters, the C-terminal 
promoter targeting subdomain is required.  It confers interaction of E1A CR3 with 
cellular sequence specific DNA binding transcription factors, including members of the 
ATF family (8, 20, 21). Mutants that delete this promoter targeting domain function as 
dominant negative mutants unless a second mutation is made in the zinc finger 
subdomain of CR3, further underscoring the promoter targeting activity of this region 
(20). The precise role of AR1 in E1A CR3 dependent transactivation remains unclear, 
however the acidic character of this region is necessary for maximal transactivation by 
the E1A CR3 region (32). 
Since the initial model was put forth, multiple additional cellular factors have been 
implicated in transcriptional activation by E1A CR3.  The S8 component of the 19S 
ATPase proteins Independent of 20S (APIS), also known as hSUG1, was shown to 
interact with E1A CR3 and enhance E1A CR3 transactivation (28).   A second interaction 
site for the cellular repressor CtBP was also mapped to the CR3 region of hAd5 E1A, and 
CtBP appears to repress E1A CR3 transactivation (7).  The p300/CBP KAT is critical for 
hAd5 E1A CR3 transactivation and binds directly to E1A CR3 independently of other 
interaction motifs in E1A (27).  Most recently, the KAT pCAF was identified to interact 
with the E1A CR3 region and enhance transactivation (26).  Many of these cellular 
factors interact with other regions of E1A besides CR3, further complicating E1A 
mediated activation of transcription. 
The vast majority of the work used to build the initial model was done exclusively with 
hAd5 E1A CR3.  Very little is known regarding how E1A CR3s from other hAd types 
activate transcription.  Alignment of the amino acid sequence of E1A CR3 from 
representative members of each hAd species, corresponding to the hAd5 E1A residues 
139-204, demonstrates their high degree of conservation (Figure 2-1A).  The amino acid 
identities and similarities to hAd5 E1A CR3 range from 34%-41% and 41%-53%, 
respectively (2).  Overall, CR3 is the most conserved domain of E1A, but it is not known 
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if the model for hAd5 E1A CR3 transactivation will apply universally to the entire hAd 
family.  Our previous work suggests that there may in fact be differences in how specific 
E1A CR3s activate transcription, as only a subset of the E1A CR3s we tested interact 
with and are influenced by pCAF (26). 
We report here the first comprehensive study of the cellular factors required for E1A CR3 
transactivation using representative E1A CR3s from each hAd species.  The panel of 
representative E1A CR3s show dramatic differences in their ability to activate 
transcription as Gal4-DBD fusions, which cannot be explained by the existing model of 
E1A CR3 function.  Systematic analysis of the roles of MED23, TBP, hSUG1 and 
p300/CBP, which have been implicated in hAd5 E1A CR3 function, reveals that these 
interactions are conserved across all hAd speciess, and each representative E1A CR3 can 
compete for common factor(s) and squelch hAd5 E1A CR3 transactivation.  However, 
the known cellular factors required by E1A CR3 cannot explain the dramatic differences 
in transactivation observed among these representative E1A CR3s.  These results 
demonstrate that many of the cellular targets utilized by hAd5 E1A CR3 are conserved 
across the hAd family, expanding the existing model of E1A CR3 transactivation to 
encompass all six speciess.  Importantly, this data also indicates that additional factors 
influencing CR3 dependent transactivation remain to be discovered.   
2.2 Materials and Methods 
2.2.1 Cells, Cell Culture and Transfections.   
Human A549, HeLa, C33A, U2OS and HT1080 cells, as well as MEFs and MED23-/- 
MEFs cells were maintained at 37 
o
C and 5 % CO2 in DMEM (Wisent) with 10 % FBS 
(Gibco) and 100 U/ml of Penicillin/Streptomycin (Wisent).  A549 cells and MEFs were 
transfected with FuGENE HD Reagent (Roche) according to the manufacturer‘s 
directions in a ratio of 3 µg to 9 µl per well of a six-well plate.  HeLa and HT1080 cells 
were transfected with Superfect reagent (Qiagen) according to the manufacturer‘s 
directions.  
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Figure 2-1:  Transcriptional Activation By E1A-CR3s From Six Human Adenovirus 
Species. 
A)  Sequence alignment of human Adenovirus E1A CR3 fragments used from 
serotypes hAd12 (species A), hAd3 (species B), hAd5 (species C), hAd9 (species D), 
hAd4 (species E) and hAd40 (species F). Asterisks indicated zinc coordinating 
cysteines. Arrows indicate residues in hAd9 E1A CR3 that differ from hAd5 E1A 
CR3 and are critical for transcriptional activation.    B) Intrinsic transcriptional 
activation properties of representative E1A CR3s.  A549, HeLa, C33A, HT1080 or 
MEF cells were co-transfected with a Gal4 responsive luciferase reporter and vectors 
expressing the indicated Gal4DBD fusions.  Luciferase activity expressed as % of 
hAd5 CR3 fold activation of above empty vector +/-SD.  Inset:  Western blot for the 
expression level of Gal4-fused CR3 domains in A549 cells using anti-Gal4 and anti-
actin as a loading control. 
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 The U2OS stable cell line containing an integrated Gal4-responsive luciferase 
reporter (U2OS-UAS) was made by co-transfection of U2OS cells with pGL2-(Gal4)6-
Luc and pcDNA3.1-Hygro in a 9:1 ratio and selection on 400 µg/ml of hygromycin.  
Hygromycin resistant pools were used for all experiments.  
2.2.2 Plasmid Construction.   
The Gal4-responisve luciferase reporter vector pGL2-(Gal4)6-Luc and Gal4DBD-fusions 
for each hAd E1A CR3 and wt HPV16-E7 have been described previously (1, 30).  
Expression vectors for EGFP fusions of hAd E1A CR3s and wt HPV E7 were cloned 
from their respective Gal4DBD-fusions into pCANmyc-EGFP with EcoRI and XbaI.  
The expression vectors for the full length E1A clones of hAd3, 4, 5, 9, 12 and 40 were 
cloned into pM (Clontech Laboratories Inc.) with EcoRI and SalI.  The expression vector 
for hMED23 (pCS2+-hSur2) was a gift from A. Berk and described previously (6).  
Expression vectors for TBP (pcDNA4HA-hTBP) and hSUG1 (pcDNA4HA-hSug1) were 
described previously (28).  The p300 expression vector was described previously (27).   
2.2.3 Gal4-Fusion Activation Assay. 
24 hours prior to transfection 1.5x10
5
 A549 cells/well were seeded on six well plates.  
Cells were transfected in a 1:1 ratio of reporter vector (pGL2-(Gal4)6-Luc): activator 
(either pM or pM-CR3).  Cells were harvested 48 hours post transfection in 1X Cell 
Culture Lysis Buffer (Promega) and assayed for Luciferase activity using STEADY-GLO 
substrate (Promega).  Relative Light Units (RLUs) were normalized to protein 
concentration and plotted as mean fold activation above Gal4-DBD alone (pM) +/- SD. 
2.2.4 Co-Immunoprecipitation and Western Blot Analysis.   
Typically, 1.5x10
6
 HT1080 cells were seeded into 10 cm plates 24 hours prior to 
transfection.  Cells were transfected in a 1:1 ratio of myc-EGFP fusion and HA-tagged 
binding partner, or myc-EGFP fusion/E1A alone if using endogenous binding partners.  
Cells were harvested 24 hours post transfection by scraping and washed once with 1X 
PBS.  Cells were lysed in either NP40 (50 mM Tris-pH7.8, 150 mM NaCl, 0.1 % NP40) 
or E1A (50 mM Hepes-pH 6.8, 230 mM NaCl and 0.5 % NP40) lysis buffer 
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supplemented with 1x mammalian protease inhibitor Cocktail (Sigma).  Typically, 1 mg 
of cell lysate was mixed with 100 µl of anti-myc hybridoma (Clone 9E10) or M73 anti-
E1A hybridoma supernatant and 125 µl of 10% slurry of ProteinA-Sepharaose resin 
(Sigma) and incubated at 4 
o
C for 1 hour with nutating.  Immunoprecipitates were 
washed five times with lysis buffer, resuspended in 1X LDS sample buffer and boiled for 
5 minutes.  Samples were then separated by SDS-page, transferred to PVDF membrane 
(GE) and blocked in 5 % Non-fat Milk in TBS-T.  Western blot analysis was carried out 
with mouse anti-myc hybridoma clone (9E10), rat monoclonal anti-HA (clone 3F10 
Roche), monoclonal anti-Rb (clone C36), rabbit anti-actin (Sigma), mouse monoclonal 
anti-TBP (Millipore), rabbit anti-hSUG1(14) or mouse monoclonal anti-p300 (clone 
Rw128 Millipore) followed by either rabbit-anti-mouse HRP (Jackson Labs), goat-anti-
rat HRP (Pierce) or goat-anti-rabbit HRP (Jackson Labs).   
2.2.5 siRNA Knockdown.   
Custom siRNA against p300 was used as described previously(27).  Silencer select 
siRNAs against TBP (siRNA ID# s13826) and hSUG1 (siRNA ID# s11381) were 
purchased from Ambion.  siRNA transfections were performed with siLentFECT reagent 
(BioRad) according to the manufacturer‘s directions.  Typically 1.5x106 HeLa cells were 
seeded on 10 cm plates for siRNA transfection.  At 24 hours post siRNA transfection, 
cells were re-seeded to 6 well plates at 2x10
5
 cells per well.  At 48 hours post siRNA 
transfection cells were transfected as described above to perform the Gal4-fusion 
activation assay. 
2.2.6 Squelching Assay.   
24 hours prior to transfection 1.5x10
5
 A549 cells/well were seeded on six well plates.  
Cells were transfected in a 1:1:1 ratio of reporter (pGL2-(Gal4)6-Luc): activator (either 
pM or pM-Ad5 CR3): squelcher (myc-EGFP fusion).  Cells were harvested 48 hours post 
transfection for luciferase assay as described above.  Relative Light Units (RLUs) were 
normalized to protein concentration and plotted as a percent of Gal4-Ad5 E1A-CR3 wt 
with EGFP (empty vector) as competitor +/- SD.  The squelching rescue assay was 
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performed as above at a 1:1:1:1 ratio including pcDNA4HA-hSUG1 or empty 
pcDNA4HA. 
2.2.7 Quantitative RT-PCR.   
Human A549 cells were infected with either hAd5 (dl309 or dl312) or wt hAd9 virus at 
MOI of 2.0 (or 200 and 2000 for hAd9 wt).  At 16 hrs post infection total RNA was 
isolated with Trizol (Invitrogen) according the manufacturer‘s directions.  For each 
sample 1 µg of total RNA was first heated to 70 °C for 5 minutes and subjected to 
DNaseI treatment (Invitrogen) according to manufacturer‘s directions.  First strand 
synthesis was performed using OligodT (Inivitrogen) and SuperScriptII (Invitrogen) 
according to manufacturer‘s directions.  A 15 µl Q-PCR reaction was performed in 
triplicate using 1X iQ-SYBRGreen SuperMix (BioRad) according to manufacturer‘s 
directions in a MyiQ Real Time PCR instrument (BioRad).  The following primers for 
hAd9 targets were used at 200 nM final concentration: RTAd913S E1AF 5'-
agctttatttacagtccggtgtcaga-3‘; RTAd913SE1AR 5'-acacttgcaggggcgttt-3‘; RTAd9E4orf6-
7F 5‘-cataatactgtgaccttggac-3‘; RTAd9E4orf6-7R 5'-tttcctggcgagccaaac-3‘.  The primers 
for hAd5 targets and GAPDH were described previously (28).  Data was analyzed using 
BioRad IQ5 sofware (BioRad); briefly, E4ORF6/7 mRNA levels were normalized to 
GAPDH as an internal control and the respective E1A mRNA level for each sample.  
E1A and E4ORF6/7 mRNA levels in dl312 (E1A deleted) infected cells were set to 1. 
2.3 Results 
2.3.1 E1A CR3 mediated transactivation differs greatly between 
hAd types.   
E1A is a potent activator of transcription and hAd5 E1A CR3 (residues 139-204) is 
sufficient to activate transcription when fused to a heterologous DBD in mammalian and 
yeast cells (26-30, 34).  We tested whether the corresponding E1A CR3 portions of hAd 
3, 4, 9, 12 and 40 E1A, which represent the other five hAd speciess were capable of 
activating transcription as Gal4-DBD fusions in the A549 human alveolar basal epithelial 
cell line (Figure 2-1B).  A549 cells were chosen as they are commonly used as a 
diagnostic cell line for clinical hAd infections.  All six E1A CR3s activated a Gal4 
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responsive promoter in A549 cells.  Interestingly, there were dramatic differences in their 
relative activities (Figure 2-1B).  Given that E1A is the first gene expressed during 
adenovirus infection and is responsible for activating viral gene expression, the current 
model would predict that all E1A CR3s should strongly activate transcription. However, 
there appeared to be three classes of E1A CR3s with respect to activation of transcription:  
species A (hAd12), C (hAd5) and E (hAd 4) E1A CR3s were the most potent activators 
of transcription, species B (hAd 3) and species F (hAd 40) E1A CR3s exhibited an 
intermediate ability, while species D (hAd 9) E1A CR3 was a weak activator.  To 
determine if these differences in activity were specific to A549 cells, we repeated these 
experiments in HeLa and C33A human cervical carcinoma cells, HT1080 human 
fibrosarcoma cells and mouse embryonic fibroblasts (MEFs).  Although some differences 
in activation were seen between cell types, hAd 9 CR3 was consistently the weakest 
activator in all cells tested (Figure 2-1B).   
2.3.2 Diverse E1A CR3s share common cellular targets.   
Since little is known about the mechanism by which the E1A CR3 regions of any hAd 
type other than hAd5 activate transcription, we first determined if there are common 
cellular factors targeted by the different E1A CR3s.  We designed a competition, or 
squelching assay to determine if there is functional overlap of cellular targets required for 
transactivation.  A549 cells were co-transfected with a Gal4-responsive luciferase 
reporter, an activator and a competitor.  In this assay the readout is the activation by 
Gal4-Ad5 E1A-CR3 wt above Gal4 alone and is expressed as a percentage of Gal4-Ad5 
E1A-CR3 wt with EGFP (empty vector) as competitor.  If a competitor does not target 
factors required by the DNA bound transactivator, the level of transcriptional activation 
should remain at 100 % regardless of the level of competitor present. However, if the 
competitor targets a factor(s) required for function by the activator, a dose dependent 
reduction of transactivation will be observed as the level of the competitor is increased.  
As expected, wt hAd5 E1A CR3 fused to EGFP potently squelched the activity of Gal4-
Ad5 E1A-CR3 wt in a dose dependent manner (Figure 2-2A).  This clearly demonstrates 
that soluble EGFP hAd5 E1A CR3, which is unable to bind the promoter, 
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Figure 2-2:  Squelching of hAd5 E1A CR3 function. 
A) Design and titration of squelching assay.  A549 cells were co-transfected with a Gal4 
responsive luciferase reporter, vectors expressing Gal4-alone or Gal4-Ad5 CR3 as activator and 
either EGFP or increasing amounts of vector expressing EGFP-Ad5 CR3 fusion as competitor.  
Luciferase activity is expressed as % fold activation above vector alone of Gal4-Ad5 CR3 with 
EGFP as competitor +/-SD. Inset:  Western blot of EGFP-CR3 expression levels and actin 
loading controls.  B) Activation of established mutants of E1A-CR3 as Gal4-fusions.  A549 cells 
were co-transfected with a Gal4 responsive luciferase reporter and vectors expressing the 
indicated Gal4 fusions to E1A-CR3 or empty vector.  Luciferase activity expressed as fold 
activation of over vector +/-SD.  C) Interaction of mutants of Ad5 E1A CR3 with known cellular 
targets of CR3.   E1A CR3 fusions were CoIP‘d with anti-myc antibody and blotted with anti-HA 
antibody for the indicated targets.  Inputs are probed with anti-myc antibody for CR3s or anti-HA 
antibody for MED23, TBP, hSUG1 or p300.  D) Squelching of E1A CR3 dependent 
transactivation by hAd5 CR3 mutants, A549 cells were co-transfected as in A) but with equal 
amounts of vectors expressing Gal4 fused to the indicated Ad5 CR3 mutants or HVPE7. Inset:  
Western blot of EGFP-fusion expression levels and actin loading controls.  E) Sequestration of 
hSUG1 is not responsible for transcriptional squelching by CR3 V147L.  Human A549 cells were 
co-transfected as in D with either empty vector [pcDNA4 (black bars)] or a hSUG1 expression 
vector [pcDNA4-hSUG1 (grey bars)] in a 1:1:1:1 ratio.  Activation in vector transfected vs. 
hSUG1 transfected cells were compared by Student‘s T-Test and P values are indicated. Inset:  
Western blot of EGFP-fusion expression levels, hSUG1 levels and actin loading controls. 
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will sequester limiting factors from promoter tethered Gal4-Ad5 E1A CR3, reducing its 
ability to stimulate transcription of the Gal4 responsive luciferase reporter. 
2.3.3 E1A mutants unable to bind multiple factors still squelch wt 
E1A activity.   
Two well characterized point mutants of hAd5 E1A CR3 that fail to transactivate, H160Y 
and V147L, were chosen to validate the squelching assay (12).  We confirmed that Gal4 
fusions of each of these mutants were unable to activate a Gal4-responsive promoter 
(Figure 2-2B).  hAd5 E1A CR3 interacts with multiple cellular transcriptional regulators 
in order to orchestrate the activation of gene transcription (25).  We determined the 
interaction profile of these mutants with respect to several of these binding partners.  
H160Y bound TBP, hSUG1, p300 and pCAF equivalently to wt hAd5 E1A CR3, but did 
not bind hMED23 (Figure 2-2C).  V147L bound hSUG1 like wt hAd5 E1A CR3, bound 
TBP only weakly, and did not bind hMed23, p300 or pCAF (Figure 2-2C).  Taken 
together these mutants represent transactivation defective mutants that retained selective 
interactions with factors that might be rate limiting for E1A CR3 dependent activation of 
transcription.  Despite the inability of these mutants to activate transcription or bind key 
transcriptional components, both effectively squelched activation by Gal4-hAd5 CR3 wt 
when expressed as soluble EFGP fusions, whereas the human papillomavirus type 16 E7 
viral transactivator did not (Figure 2-2D).  As both the H160Y and V147L mutants 
remained capable of interacting with hSUG1 similarly to wt hAd5 E1A CR3, it remained 
possible that hSUG1 is the limiting factor required by CR3 to activate transcription.  We 
tested whether over expression of hSUG1 would reverse the squelching by the V147L 
mutant.  Over expression of hSUG1 resulted in no significant change is the squelching 
activity of the V147L point mutant (Figure 2-2E).  The observation that these mutants 
lost interaction with multiple cellular factors, yet still managed to squelch wt hAd 5 E1A 
CR3 transactivation demonstrates that E1A CR3 dependent activation of transcription is a 
complex process requiring the concerted action of multiple factors.  Importantly, this data 
provides evidence that additional factors beyond hMED23, hSUG1, p300, pCAF and 
TBP are critical for hAd5 CR3 transactivation. 
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2.3.4 E1A CR3s universally squelch hAd5 E1A CR3 function.   
Little is known about the cellular factors required for CR3 dependent transactivation by 
the E1A proteins of hAd types other than hAd 5.  We hypothesized that the squelching 
assay could be applied to determine if the E1A CR3 regions of other hAd types 
functioned via interaction with the same set of cellular transcriptional regulators.  A549 
cells were co-transfected with a Gal4 responsive luciferase reporter and Gal4- hAd5 E1A 
CR3 wt as described before, with EGFP fused to the E1A CR3 regions of chosen 
representative hAds as competitors.   The E1A CR3 regions of all six hAd types were 
capable of squelching hAd5 CR3 dependent activation, although to varying extents 
(Figure 2-3A).  Three classes of squelching ability were observed: hAd5 and hAd4 E1A 
CR3s were the most potent, hAd3 E1A CR3 appeared to have an intermediate ability and 
hAd12, hAd9 and hAd40 E1A CR3 were the least effective squelchers (Figure 2-3A 
Inset).  Weaker squelching was not simply due to low levels of expression as determined 
by western blot (Figure 2-3A).  Interestingly, the effectiveness of an individual CR3 
region to squelch was not typically related to its ability to activate transcription as a Gal4-
DBD fusion (Figure 2-3B). 
Based on the squelching assay, it was clear that the chosen representative E1A 
CR3s targeted cellular transcriptional regulators also required by hAd5 E1A CR3.  We 
therefore systematically examined their interactions with known coactivators of E1A 
CR3, including MED23, TBP, hSUG1 and p300, as well as the functional requirements 
for these interactions.   
2.3.5 MED23 is required by all E1A CR3s to activate transcription.   
The Mediator component MED23 has been implicated to be the most critical cellular 
coactivator of hAd5 CR3 function (6, 31).  This interaction is also required for murine 
AdV growth, suggesting that this factor may be universally utilized by different 
adenovirus types (10).  We tested the ability of the full length E1A product from each 
representative hAd species to interact with hMED23 by Co-IP.  Each of the different full 
length E1A proteins bound hMED23, although none bound it as strongly as hAd5 E1A 
(Figure 2-4A).  Furthermore, the E1A CR3 domains of each representative E1A 
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Figure 2-3:  Squelching of hAd5 E1A CR3 dependent activation by the CR3 domains 
from representative hAd types 
A) Human A549 cells were co-transfected with a Gal4 responsive luciferase reporter, 
vectors expressing Gal4-alone or Gal4-hAd5 CR3 as activator and either EGFP or EGFP-
fused to each of the indicated E1A-CR3 fusion to mycEGFP as competitor.  Inset:  
Western blot of EGFP-fusion expression levels and actin loading controls.  Luciferase activity 
is expressed as % fold activation of Gal4-hAd5 CR3 above vector alone with EGFP as 
competitor +/-SD. B)   Summary of transcriptional properties of representative E1A 
CR3s.  The transcriptional activation, squelching and expression level of each E1A CR3 
are summarized relative to hAd5 E1A CR3. 
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Figure 2-4:  MED23 is targeted by E1A CR3s from multiple hAd types. 
A)  Co-IP of MED23 and the 13S encoded E1A proteins from each hAd subgroup.  Human 
HT1080 cells were co-transfected with a vector expressing HA-tagged human MED23 and 
vectors expessing either EGFP or an EGFP-fused to the indicated E1A proteins.  E1As were 
immunoprecipitated with anti-EGFP antibody and blotted with anti-HA antibody.  Inputs were 
probed with EGFP antibody for E1As or HA antibody for MED23.  B) Co-IP of MED23 with the 
E1A CR3 domains from each hAd subgroup.  Human HT1080 cells were co-transfected with 
vectors expressing HA-tagged human MED23 and either myc-EGFP or a myc-EGFP-fused to the 
indicated E1A CR3 domain.  E1A CR3 domains were immunoprecipitated with anti-myc 
antibody for myc-tagged CR3 and blotted with anti-HA antibody for HA tagged MED23.  Inputs 
were probed with anti-myc antibody for CR3s or anti-HA antibody for MED23.  C)  E1A CR3 
activation in MED23 null MEFs.  MED23 null MEFs and wt littermate derived MEFs were co-
transfected with a Gal4 responsive luciferase reporter and vectors expressing Gal4 fused to the 
indicated E1A CR3 domain (white and black bars respectively).  MED23 null MEFs were also 
transfected with the Gal4 responsive luciferase reporter, vectors expressing the indicated Gal4-
E1A CR3 domain fusions and an expression vector for human MED23 (grey bars).  Luciferase 
activity is expressed as fold activation over Gal4DBD alone +/-SD 
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protein were sufficient for this interaction (Figure 2-4B).  In order to determine the 
functional consequences of this hMED23 interaction, the ability of the representative 
E1A CR3s to activate transcription in MED23 null (MED23 -/-) MEFs was determined.  
All six E1A CR3s activated transcription in wt MEFs, but failed to activate transcription 
in MED23 -/- MEFs (Figure 2-4B, black bars and white bars, respectively).  The failure 
to activate transcription was rescued by the expression of exogenous hMED23 in the 
MED23-/- MEFs (Figure 2-4C, grey bars).  We conclude that hMED23 is a common 
target of each of the six representative CR3s and is absolutely required for 
transactivation. 
2.3.6 TBP binds all E1A CR3s but is not required for 
transcriptional activation.   
The first cellular protein shown to interact with CR3 of hAd5 E1A was TBP (19).  We 
tested if TBP was a conserved interaction among the different E1A CR3s and also 
determined the requirement for TBP in E1A CR3 dependent activation of transcription.  
hAd5 E1A CR3 was sufficient to Co-IP TBP, and the five other E1A CR3s interacted 
with hTBP at least as strongly as hAd 5 E1A CR3 (Figure 2-5A).  As a negative control 
for these interaction studies, we assessed the ability of the E1A CR3 fusions to Co-IP 
pRb, which binds E1A primarily via CR2.  As expected, none of the E1A CR3 fusion 
proteins bound pRb (Figure 2-5B).  To determine the functional role of TBP in E1A CR3 
transactivation, we depleted TBP in HeLa cells by RNAi and then examined the ability of 
each E1A CR3s to activate transcription as a Gal4-fusion in control siRNA vs. TBP 
specific siRNA treated cells.  siRNA knockdown of TBP did not reduce transactivation 
by any of the six CR3s tested (Figure 2-5C).  Based on this observation we conclude that 
although TBP is a conserved target of the six CR3s, it does not appear to be nearly as 
critical as hMED23 for transactivation.   
2.3.7 hSUG1 binds all E1A CR3s and contributes to transcriptional 
activation.   
The proteasome is a crucial cellular coactivator of hAd5 E1A and CR3 binds the 
proteasome via the hSUG1 or S8 ATPase proteasome components (28).  All six 
representative E1A CR3s interacted with hSug1 as determined by Co-IP (Figure 2-6A).  
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A)  Co-IP of TBP with representative E1A-CR3s.  HT1080 cells were co-transfected with a 
vector expressing HA-tagged-TBP and vectors expressing the indicated E1A CR3s fused to 
EGFP.  E1A CR3s were immunoprecipitated with 9E10 antibody and blotted for HA (TBP).  B) 
Negative Co-IP of pRb with representative E1A CR3s.  HT1080 cells were co-transfected with 
vectors expressing the indicated E1A CR3s fused to EGFP or genomic E1A as positive control.  
E1A CR3s were immunoprecipitated with 9E10 antibody and E1As were immunoprecipitated 
with M73 and blotted for endogenous pRb. C) siRNA knockdown of TBP and the effect on 
transcriptional activation by E1A CR3.  HeLa cells were transfected with 5 nM siRNA 
(Negative control or TBP specific) and at 2 days post siRNA transfection re-transfected with a 
Gal4-reponsive luciferase reporter and an expression vector for the indicated Gal4-CR3 fusions.  
At 48hours post tranfection (120 hours post siRNA transfection) cells were harvested and 
assayed for luciferase activity.  Luciferase activity is expressed as fold above Gal4DBD alone 
+/- SD.  Activation in control vs TBP knockdown were compared by student‘s T-test and the p-
values are indicated. Inset:  Western Blot of levels of TBP in knockdown and control cells and 
actin loading controls. 
Figure 2-5:  TBP is a conserved cellular target of E1A CR3 from multiple hAd types. 
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A)  Co-IP of hSUG1 with representative hAd E1A CR3s.  HT1080 cells were co-
transfected with pcDNA4HA-hSUG1 and vectors expressing the indicated E1A CR3s 
fused to myc-EGFP.  E1A CR3s were immunoprecipitated with anti-myc antibody and 
blotted for HA.  B)  siRNA knockdown of hSUG1 and the effect on transcriptional 
activation by E1A CR3.  HeLa cells were transfected with 5 nM siRNA (Negative 
control or hSUG1 specific) and at 2 days post transfection re-tranfected with a Gal4-
reponsive luciferase reporter and an expression vector for the indicated Gal4-CR3 
fusions.  At 48 hours post transfection (120 hours post siRNA transfection) cells were 
harvested and assayed for luciferase activity.  Luciferase activity is expressed as fold 
above Gal4DBD alone +/- SD.  Fold activation of control vs hSUG1 siRNA treated cells 
were compared by students t-test and P Values are indicated. Inset:  Levels of hSUG1 in 
knockdown and control cells. 
Figure 2-6:  Human SUG1 is a conserved target of E1A-CR3 from multiple hAd types. 
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RNAi directed knockdown of hSUG1 resulted in a reduction of transactivation by all six 
different E1A CR3s.   In particular, the E1A CR3s capable of potent activation of 
transcription (hAd12, hAd5, hAd4 and hAd40 CR3s) showed a significant loss of activity 
in hSUG1 siRNA treated cells relative to control (Figure 2-6B).  
2.3.8 p300/CBP is required by all E1A CR3s to activate 
transcription.   
We have previously shown that the p300/CBP KATs also function as a critical co-
activator of hAd5 E1A CR3 function (27).  All six representative E1A CR3s interacted 
with p300 as determined by Co-IP, although hAd5 E1A CR3 showed the strongest 
interaction (Figure 2-7A). Depletion of p300 levels by siRNA resulted in a greater than 
50 % reduction in CR3 transactivation for all six E1A CR3s (Figure 2-7B), and this was 
statistically significant for all but hAd9 E1A CR3, the weakest activator. 
Taken together, these data indicate that each of the six different hAd E1A CR3s share 
these four cellular transcriptional regulators as common targets.  Importantly, the relative 
differences between each of these E1A CR3s to activate transcription or squelch hAd5 
E1A CR3 activity cannot be simply explained by differences in their association with 
these factors. 
2.3.9 Transcriptional activation by full-length E1A proteins.   
We reasoned that the surprisingly large differences in the intrinsic ability of the different 
CR3s to activate transcription could be functionally compensated by activities present in 
other portions of these proteins.  Indeed, it is well established that the N-terminal/CR1 
region of hAd5 E1A functions as a strong activator of transcription when tethered to a 
heterologous DNA binding domain (5, 30).  We directly compared the ability of the 
different CR3s with the corresponding full length E1A proteins to activate transcription 
of a Gal4 responsive luciferase reporter stably integrated into the genome of U2OS 
human osteosarcoma cells (Figure 2-8A).  While there were again marked differences in 
the activities of the different E1A CR3s, the full-length E1A proteins were all equivalent 
or superior activators with respect to hAd5 E1A.  This was particularly pronounced for 
hAd9, suggesting that other regions of this E1A protein may compensate for the weak 
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A)  Interaction of p300 with the E1A CR3 domains of different hAd types.  Human 
HT1080 cells were co-transfected with an expression vector for HA-tagged p300 and 
expression vectors for the indicated E1A CR3 myc-EGFP fusions.  EGFP fusions were 
immunoprecipitated with a cocktail of 9E10 and GFP antibody and blotted with HA.  B) 
Effect of siRNA depletion of p300 on E1A CR3-dependent activation. HeLa cells were 
transfected with 20 nM custom siRNA directed against p300 or control siRNA and at 3 
days post transfection re-tranfected with a Gal4-reponsive luciferase reporter and an 
expression vector for the indicated Gal4-CR3 fusions.  At 48 hours post transfection 
(120 hours post siRNA transfection) cells were harvested and assayed for luciferase 
activity.  Luciferase activity is expressed as fold above Gal4DBD alone +/- SD. Fold 
activation of control vs p300 siRNA treated cells were compared by students t-test P 
Values are indicated.  Inset:  Levels of p300 in knockdown and control cells. 
Figure 2-7:  p300 is a conserved target of E1A CR3 from multiple hAd types. 
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A)  Transactivation by full length E1As in the context of Chromatin.  U2OS-UAS 
cells that contain an integrated Gal4-responsive luciferase reporter were 
transfected with expression vectors for either the indicated E1A CR3 domains 
(black bars) or the indicated full length 13S E1As (grey bars).  Luciferase activity 
is expressed as fold activation above Gal4 alone +/-SD. B) Transactivation of the 
hAd5 and hAd9  E4 promoters.  At 16 hrs post infection with the indicated 
viruses the expression level of E4ORF6/7 mRNA was determined by qRT-PCR.  
The expression level of E4ORF6/7 relative to GAPDH and E1A is indicated, and 
the expression level for cells infected with dl312 is set to 1. 1x, 10x and 1000x 
denote MOIs of 2, 20 and 2000 respectively.  
Figure 2-8:  Transactivation by Full Length E1A 
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intrinsic transcriptional activation function of hAd9 E1A CR3.   We looked further at the 
activity of the hAd9 E4 promoter in the context of viral infection by qRT-PCR, as E4 is a 
well documented target of E1A transactivation.  During infection, the relative expression 
level of E4ORF6/7 mRNA was greatly elevated in the presence of wt hAd5 E1A as 
compared to infection with an E1A deleted hAd5 virus (~1500 fold increase).  This is 
expected because E4 expression is highly responsive to full length E1A (22). The relative 
expression level of the E4ORF6/7 mRNA in hAd9 infected cells exceeds that of wt hAd5 
infected cells, similar to what was seen with the integrated reporter assay (Figure 2-8B).  
The expression level of E4ORF6/7 in hAd9 infected cells increased in a dose dependent 
manner with increased viral inoculum (Figure 2-8B).  Assuming that the hAd9 
E4ORF6/7 mRNA is similarly regulated by E1A, it is clear that the hAd9 early genes are 
potently activated upon infection.  This supports our observation with an integrated 
reporter gene (Figure 2-8A) that full length hAd9 E1A retains strong transactivation 
function, despite the weak activity intrinsic to CR3 alone.  
2.4 Discussion 
The CR3 portion of hAd5 E1A is a potent transcriptional activation module and serves as 
a paradigm of viral transactivation (3, 11, 25).    CR3 is the most highly conserved of the 
four conserved regions within E1A (Figure 2-1A) (2).  Given this similarity between E1A 
proteins and their essential role in activating virus early gene expression, one would 
predict that all E1A CR3s would function as potent activators of transcription.  However 
this is not the case; there are dramatic differences in the potency of representative E1A 
CR3s to activate transcription (Figure 2-1B).   In the experiments described here it was 
critical to utilize E1A CR3s fused to the Gal4-DBD.  Direct tethering of the E1A CR3 
activation domain to the transcriptional reporter via fusion to the Gal4DBD allows a 
direct comparison of the transactivation function by bypassing any differences in affinity 
between the various E1A CR3s and the sequence specific DNA-binding transcription 
factors that normally recruit it to the transcriptional template (20, 21).  Indeed, our initial 
experiments revealed that none of the largest E1A products from any of the hAd speciess 
(except hAd 5) could stimulate transcription of an hAd 5 E4 promoter driven reporter, 
presumably due to an inability to be targeted to that reporter (unpublished results).    
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 The unexpected and dramatic differences between the different E1A CR3 
domains to activate transcription suggest that the hAd lifecycle can initiate and progress 
efficiently even if the CR3 region of the E1A protein is a relatively weak activator.  
Indeed, 3 of the 5 other E1A CR3s we tested were less that 50 % as active as the 
prototype hAd 5 E1A CR3, with hAd9 E1A CR3 being by far the weakest (Figure 2-1B).   
In agreement with this, previous work using a panel of E1A CR3 mutants found that 
growth of hAd5 was not significantly reduced unless E1A dependent transactivation was 
reduced by 5 to 20 fold, which translates to the suggestion that a minimum cut-off of 
approximately 20 % of hAd 5 E1A CR3 function is critical to virus growth (16).   
 To understand the molecular basis for the differences in transactivation between 
hAd types, we initially utilized a transcriptional squelching assay.  Despite the inability 
of the hAd V147L E1A CR3 mutant to interact with multiple cellular proteins targeted by 
E1A CR3 (MED23, TBP, pCAF and p300), it behaved nearly like wt hAd5 E1A CR3 in 
the squelching assay.  This is highly indicative that this mutant retains binding to 
additional limiting factors necessary for E1A CR3 dependent transactivation that remain 
to be identified.  When tested in the squelching assay, expression of each of the five other 
representative E1A CR3s as fusions to EGFP reduced activation by Gal4-hAd 5 E1A 
CR3 (Figure 2-3A).  These results confirmed that each of the distinct hAd E1A CR3 
domains was capable of competing with Gal4-hAd 5 E1A CR3 for at least one critical 
factor.  Interestingly, there did not appear to be any correlation between the potency of a 
given E1A CR3 to transactivate (Figure 2-1B) and the ability to squelch hAd5 E1A CR3 
(Figure 2-3B).  These results suggest that the mechanism of E1A CR3 transactivation is a 
complex hierarchy of binding kinetics and that multiple cellular factors required by E1A 
CR3 are limiting in vivo.  Simply put, the extent to which any given E1A CR3 squelches 
Gal4-hAd 5 E1A CR3 is based on its ability to sequester one or more of these targets.  
Furthermore, the ability of hAd 12 E1A CR3 to activate as strongly as hAd 5 E1A CR3 
yet squelch Gal4-hAd 5 E1A CR3 poorly, indicates that important mechanistic 
differences in transactivation exist between at least these two E1A proteins.  One 
explanation for these observations could be that hAd 12 E1A CR3 targets additional 
factors not utilized by hAd5 E1A CR3 that contribute to its strong transactivation 
function (15).  
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 We directly tested the ability of each of the six E1A CR3 domains from the 
different hAd types to bind hMED23 (Figure 2-4B), TBP (Figure 2-5A), hSUG1 (Figure 
2-6A) and p300 (Figure 2-7A) and the role that these interacting proteins had on their 
ability to transactivate (Figures 2-4C, 2-5B, 2-6B and 2-7B, respectively).  These data 
demonstrated, for the first time in most cases, that each of the different E1A CR3s had 
the ability to interact with  these cellular factors, although to varying extents with respect 
to the hAd 5 E1A CR3 prototype.  These data also demonstrate that hMED23, hSUG1 
and p300 play vital roles in transactivation by most, if not all, of the different E1A CR3s, 
as previously described for the hAd 5 E1A CR3 prototype (27, 28, 31).  In contrast, the 
interaction with TBP is not necessary for transcriptional activation by the different CR3s, 
at least in the context of the Gal4-CR3 fusions.   
 The binding data demonstrated that hAd 9 E1A CR3 interacted to some degree 
with all of the known cellular targets of E1A CR3 tested (Figures 2-4B - 2-7B).  Indeed, 
it bound hMED23 (Figure 2-4A) and pCAF far better than all other E1A CR3s except 
hAd5 (26).  Based on the binding data, it is not surprising that hAd9 E1A CR3 squelched 
hAd5 E1A CR3-dependent activation (Figure 2-3).   However, it is surprising that it was 
the weakest activator of transcription of the six E1A CR3s tested.  The existing model of 
E1A CR3 function cannot explain this phenomenon.  According to what is currently 
known about E1A CR3 function, hAd9 E1A CR3 should be able to potently activate 
transcription as a Gal4-fusion because it can interact strongly with all of the known 
cellular coactivators of E1A CR3 so far identified.  This line of evidence may indicate 
that the weak activity of the hAd9 E1A CR3 region results from the involvement of an as 
yet unidentified cellular co-factor required by E1A CR3 to activate transcription.  
Alternatively, if E1A CR3 serves as a scaffold to assemble all the factors required for 
transcriptional activation, hAd 9 E1A CR3 on its own may not properly organize them 
spatially or temporally. 
 Interestingly, the hAd9 E1A CR3 sequence has the least identity with hAd5 
(47%), as compared to hAds 12, 3, 4 and 40 (60%, 60%, 56% and 54% respectively).  
The key residues essential for transcriptional activation by hAd5 CR3 have been 
systematically identified (33).  Based on that analysis, inspection of the CR3 sequence of 
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hAd9 E1A reveals that multiple residues expected to be critical for activation are 
different.  Specifically, individual conservative changes in L144, G151, M170 and R177 
significantly impair hAd 5 E1A CR3 activation and these residues all differ in hAd9 E1A 
CR3 (Figure 2-1A).   Despite the pronounced defect in hAd9 E1A CR3 dependent 
activation, the full length hAd9 E1A protein is a very potent activator (Figure 2-8A), and 
the hAd9 E4 promoter is highly active upon infection (Figure 2-8B) suggesting that other 
regions of the protein can effectively complement the deficiency in CR3 to activate viral 
early gene expression.       
From the work presented here, it is clear that there are multiple conserved interactions 
amongst the representative E1A CR3s with cellular co-factors that are involved in 
activating transcription.  Beyond these conserved interactions, our current and previous 
work (26) also provides growing evidence that there are selective cellular targets required 
by the E1A CR3 domains of some hAd types and not others.  These may be particularly 
important for infection of specific tissues types.  Perhaps it is the subtle differences in 
accessory factors that ultimately regulate the potency of a given E1A CR3 to activate 
transcription, rather than the conserved co-activators.  Further studies of these potent 
transcriptional activation domains may lead to the identification of additional cellular 
transcriptional regulators and provide novel insight into their mechanism of action. 
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Chapter 3  
3 Cellular GCN5 is a Novel Regulator of Human 
Adenovrius E1A-Conserved Region 3 Transactivation 
3.1 Introduction 
The early region 1A (E1A) gene is the first viral gene expressed in cells upon infection 
with human adenovirus (hAd). The primary E1A transcript is alternatively spliced to 
yield two predominant isoforms early in infection that perform the two essential functions 
required to initiate the viral replication cycle. Firstly, E1A uncouples the cell cycle 
control program of the host cell, driving it into S phase to provide an optimal cellular 
environment for viral replication. The smaller major E1A isoform (243 residues in hAd5 
E1A) is sufficient to override cell cycle progression and drive cells into S-phase (18, 36). 
The other critical function of E1A is to activate transcription of the early viral promoters, 
also known as transactivation.  Transactivation of the hAd early genes is predominantly 
mediated by the product of the largest E1A isoform (7, 24, 33, 34). In hAd5 the 13S E1A 
mRNA codes for a 289 residues protein that differs from the 243R E1A protein by a 
unique 46 aa C4 zinc finger domain located within CR3, which is essential for viral 
transactivation (7, 24). Chemical mutagenesis of hAd originally isolated mutants with a 
host range limited to HEK293 cells, which supply wt E1A in trans. These ―host range‖ 
mutations render E1A unable to transactivate viral promoters, thus preventing virus 
growth in HeLa cells (which do not supply E1A in trans) at a low multiplicity of 
infection (MOI) (21, 22).  Transactivation by E1A CR3 has been studied predominantly 
with hAd5, and this has established a model for CR3 function. The region of hAd5 E1A 
spanning residues 139 to 204 (which includes CR3) is not only critical for the 5-20 fold 
activation of viral transcription necessary for virus growth, but is also sufficient for 
potent activation of a minimal Gal4-responsive promoter as a Gal4-DNA binding domain 
(DBD) fusion (23, 44).  
This 65 aa region of E1A spanning residues 139-204 which includes CR3 can be further 
subdivided into the three following subdomains: an N-terminal zinc finger region, a 
promoter targeting region, and a region known as auxiliary region 1 (AR1) (15, 29, 48). 
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The existing model of CR3 transactivation states that the N-terminal zinc finger 
subdomain of E1A CR3 activates transcription by interacting with cellular TBP and 
MED23 proteins (9, 27, 47). The Mediator component MED23 is absolutely essential to 
E1A CR3 function, since CR3 fails to activate transcription in MED23-null MEFs (47). 
The requirement for MED23 by CR3 is shared between the CR3 domains of E1A 
proteins of closely related hAds. Indeed, the CR3 regions of E1A proteins from hAds 
representing the six hAd species all bind MED23 and require MED23 to activate 
transcription as Gal4 DNA Binding Domain (Gal4DBD) fusions (1).  Even very 
divergent Ads require MED23, because mouse adenovirus type 1 is unable to replicate 
efficiently in MED23-null MEFs (17).  Re-targeting of a functional E1A-containing 
transcription initiation complex to the early viral promoters requires the C-terminal 
promoter targeting subdomain of CR3. This subdomain confers interaction of E1A CR3 
with cellular sequence-specific DNA-binding transcription factors, including members of 
the ATF family (13, 29-31). Mutants that delete this promoter targeting domain of CR3 
function as dominant-negative mutants, unless a second mutation is made in the zinc 
finger domain of CR3 (29, 50). The precise role of the residues constituting the 
AR1subdomain of CR3 in transactivation remains unclear; however, the acidic character 
of this region is necessary for maximal transactivation by E1A CR3 (48).  
Since the definition of the initial model of E1A transactivation, several additional cellular 
factors have been implicated in transactivation by E1A CR3. The S8 component of the 
19S APIS, hSUG1, was shown to interact with E1A CR3 and enhance E1A CR3 
transactivation (39). A second independent interaction site for the cellular repressor C-
terminal Binding Protein (CtBP) was also mapped to the CR3 region of hAd5 E1A, yet 
CtBP appears to repress E1A CR3 transactivation (11). The p300/ CBP Lysine Acetyl-
Transferases (KATs) are critical for hAd5 E1A CR3 transactivation.  These KATs were 
shown to bind directly to E1A CR3 independently of the other two interaction motifs in 
the N-terminus and CR1 of E1A (38).  Most recently, the KAT p300/CBP associated 
factor (pCAF) was identified to interact with a subset of our panel of representative E1A 
CR3s in addition to its independent interaction with the N-terminus of E1A and to 
enhance CR3 transactivation (37).  These core co-activators and their functions are 
conserved across the entire hAd family despite dramatic differences in the magnitude of 
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E1A transactivation exhibited by representative members of each hAd species (1, 37).  
Moreover, competition experiments demonstrated that additional as yet unidentified 
cellular factors are not only involved in E1A transactivation, but and are also limiting in 
the cell (1). 
Many cellular factors that interact with CR3 also independently bind other regions of 
E1A, further complicating E1A-mediated activation of transcription.  Whether these 
independent interactions function cooperatively or competitively has not been fully 
elucidated (38, 52).  Of the factors that interact with both transactivation regions of E1A, 
two are KATs (p300/CBP and pCAF).  Our lab has identified a second interaction site for 
both of these KATs within CR3 and characterized their role in E1A transactivation (37, 
38).  A third KAT and close relative of pCAF, GCN5 also interacts with the N-terminus 
of E1A but neither a role for GCN5 nor an interaction for GCN5 within CR3 has been 
demonstrated in mammalian cells (26).  In yeast, which lack pCAF, yeast GCN5 interacts 
with hAd5 CR3 and is a coactivator of CR3 transactivation (44).   
The primary function of GCN5 appears to be as a chromatin remodelling factor (5, 10, 
35, 42).  GCN5 is a catalytic component of the Spt-Ada-GCN5-Acetyltransferase 
(SAGA) complex in yeast and the Spt-TAFII31-GCN5L (STAGA) complex in 
mammalian cells.  The KAT activity of GCN5 is required to acetylate histone H3 lysine 9 
(K9) and K14, and this facilitates transcription elongation by relaxing nucleosomes (5, 
10, 35, 42).  In mammalian cells, GCN5 plays a major role in acetylation of K14 on H3 
and concurrent phosphorylation, so-called tandem phosphoacetylation, of S10 required 
for transcriptional activation (32).  A definitive role for GCN5 in mammalian 
transcription has remained elusive, mainly due to the developmental phenotype of 
knockout animals.  pCAF null animals (pCAF -/-) are viable due to compensation by 
increased levels of GCN5, suggesting some functional redundancy between these closely 
related KATs  (55).  However, GCN5 null embryos (GCN5-/-) die very early in 
development, at 10.5 days postcoitum (d.p.c) from massive apoptosis.  This results from 
the loss of the deubiquitination activity of GCN5, and ultimately results in genomic 
instability and telomere crisis (2, 53).  Embryos specifically defective for the GCN5 KAT 
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activity (GCN5 hat/hat) die at 16.5 d.p.c as a result of defects in neural tube closure and 
encephalopathy (12). 
We report here identification of a second independent conserved GCN5 binding site 
within CR3, mapping to residues 178-184 of hAd5 E1A.  GCN5 associated with the viral 
E4 promoter in an E1A-dependent manner. Moreover, the two interaction sites in E1A 
cooperate to recruit GCN5 to the transcriptional template. GCN5 functions as a negative 
regulator of E1A transactivation, because RNAi depletion of GCN5 increased E1A 
transcriptional activation and ectopic expression of GCN5 repressed it.  Pharmacological 
inhibition or mutation of the KAT activity of GCN5 relieved the repressive effect on E1A 
transactivation and KAT inhibition also decreased virus yield.  We therefore show that 
GCN5 contributes a new layer of negative regulation to the existing model of E1A 
transactivation that influences virus production.  This activity may balance viral gene 
expression needed for replication while minimizing production of high levels of toxic 
gene products that would kill infected cells prematurely. 
3.2 Materials and Methods 
3.2.1 Cells, cell culture and transfections.   
Human A549, HeLa and  HT1080 cells, as well as wt MEFs and GCN5 hat/hat MEFs 
(12), were maintained at 37 °C and 5 % CO2 in Dulbecco modified Eagle medium 
(Wisent) with 10 % fetal bovine serum (Gibco) and 100 U/ml of penicillin-streptomycin 
(Wisent). A549 cells and MEFs were transfected with the FuGENE HD reagent (Roche), 
according to the manufacturer‘s directions, in a ratio of 3 µg of total DNA to 9 µl of 
FuGENE HD per well of a six-well plate. HeLa and HT1080 cells were transfected with 
the Superfect reagent (Qiagen), according to the manufacturer‘s directions.  Wild type 
littermate MEFs and GCN5 hat/hat MEFs were provided by Sharon Roth-Dent and have 
been described previously (12). 
3.2.2 Plasmid construction.  
The Gal4-responsive luciferase reporter vector pGL2-(Gal4)6-Luc and Gal4-DBD fusions 
for each hAd E1A CR3 and the N-terminus of E1A (residues 1-82) have been described 
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previously (3, 43). The expression vector for enhanced green fluorescent protein (EGFP) 
fusions of hAd5 E1A CR3 Δ178-184 was produced by PCR amplification of the CR3 
region using the primers CR3N-F 5‘- AGACGAATTCGGTGAGGAGTTTGTGTTA-3‘ 
and CR3C-R 5‘- CGCGGATCCATTAGGTAGGTCTTGCAGGCTC-3‘ from a 13S E1A 
dl114 clone as template with Phusion polymerase according to the manufacturer‘s 
directions.  The PCR product was cloned into pCAN-myc-EGFP with EcoRI and XbaI 
(23). The expression vector for mGCN5 was generated by PCR using the primers 
hGCN5-F 5‘-TCGGAATTCGCGGAACCTTCCCAGGCCCCAAACC-3‘ and hGCN5-R 
5‘- GACTCTAGACTACTTGTCGATGAGCCCTCC-3‘ with Phusion polymerase 
(NEB) according to the manufacturer‘s directions using a previously described 
expression vector for mGCN5 as template (54).  The PCR product was digested with 
EcoRI and XbaI and cloned into the EcoRI and NheI sites of pCMX-FLAG.  A correct 
clone was verified by sequencing. 
3.2.3 E1A transactivation assays.  
The Gal4 fusion activation assay has been described previously (1).  The full length E1A 
activation assay was performed as follows:  At 24 h prior to transfection, 1.5 x 10
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HT1080 cells/well were seeded on six-well plates. Cells were transfected in a 1:3:4 ratio 
of E4 reporter pGL2-E4v3: E1A expression vector: GCN5 (either pCMX-FLAG mGCN5 
or empty pCMX-FLAG as control) (38).  At 6 hours post-transfection cells were washed 
and fresh media was added.  For activation assays involving the GCN5 specific KAT 
inhibitor cyclopentylidene-[4-(4′-chlorophenyl)thiazol-2-yl)hydrazone (CPTH2) (Sigma), 
either the indicated final concentration of CPTH2 or equal volume of DMSO (vehicle) 
was added after washing at 6 hours post-transfection.  Cells were harvested at 48 hours 
post-transfection and assayed for luciferase activity.  Luciferase activity is expressed as 
% of control +/-SD.   
3.2.4 Co-immunoprecipitation and Western blot analysis.   
Co-immunoprecipitation (Co-IP) of GCN5 with full length E1A from infected HeLa cells 
was performed as described previously (26).  Co-IP of GCN5 with EGFP-fused CR3s 
was performed as described previously with anti-myc antibody (Clone 9E10) (1).  Co-IP 
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of mycEGFP-fused CR3 and CR3 mutants with FLAG-tagged-GCN5 was performed as 
described previously but using FLAG-M2 Agarose (Sigma) (1).  Western blot analysis 
was performed as described previously (1). The GCN5 rabbit polyclonal antibody was a 
gift from Joseph Torchia (UWO). 
3.2.5 siRNA knockdown.   
Silencer select siRNAs against GCN5 (siRNA ID 5659) was purchased from Ambion. 
siRNA transfections were performed with siLentFECT reagent (Bio-Rad), according to 
the manufacturer‘s directions. Typically, 1.5 x 106 HeLa cells were seeded on 10 cm 
plates for siRNA transfection.  At 24 h post-siRNA transfection, cells were reseeded to 
six-well plates at 2 x 10
5
 cells per well.  At 48 h post-siRNA transfection, cells were 
transfected again as described above with the appropriate expression vectors to perform 
the Gal4 fusion activation assay. 
3.2.6 Chromatin Immunoprecipitation (ChIP) assays.   
ChIP assays were preformed as described previously (38, 49).  M73 hybridoma 
supernatant was used for ChIP of E1A from infected cells and rabbit polyclonal anti-
GCN5 (a gift from Joeseph Torchia) was used for ChIP of GCN5.  PCR for a 300 bp 
region of the Ad5 E4 promoter was performed as described previously (38). 
3.2.7 Quantitative Reverse Transcription-PCR (qRT-PCR).  
Realtime qRT-PCR of hAd E4ORF6/7 transcripts were performed as described 
previously (1).  Briefly, human A549 cells were infected with either wt hAd5 or mutant 
hAd5 virus at an MOI of 2.0. At 16 h post-infection, total RNA was isolated as described 
previously and used to generate cDNA. Quantitative PCR was performed in triplicate 
with a 15 µl reaction mixture and 1x iQ-SYBR green SuperMix (Bio-Rad) according to 
the manufacturer‘s directions in a MyiQ real-time PCR instrument (Bio-Rad).  The 
primers for hAd5 targets and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 
described previously (39).  Data were analyzed using IQ5 software (Bio-Rad).  
E4ORF6/7 mRNA levels were normalized to GAPDH levels as an internal control and to 
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the respective E1A mRNA level for each sample. E1A and E4ORF6/7 mRNA levels in 
cells infected with ΔE1A mutant dl312 were set equal to 1. 
3.2.8 Virus Growth Assay 
A549 cells were infected at an MOI of 5 with either wt (dl309) or E1A deleted (dl312) 
adenovirus for one hour.  After one hour adsorption virus innoculum was removed and 
cells were replenished with fresh media contain either 50µM CPTH2 or an equivalent 
volume of DMSO (Vehicle).  At 96 hours post infection cells and media were harvested 
and subjected to three freeze-thaw cycles and the yield of virus present was determined 
by plaque assay on 293 cells.  The virus yield from duplicate experiments was averaged 
and mean virus growth +/-SD was plotted and compared by students T-test.  
3.3 Results 
3.3.1 There is a second independent interaction site for GCN5 in 
E1A that maps to the CR3 domain. 
Human GCN5 was previously shown to interact with hAd5 E1A through residues 26-35 
in its N-terminus (26). We confirmed that 12S (243R) E1A Δ26-35 failed to co-
immunoprecipitate (Co-IP) GCN5, yet this mutant can still Co-IP pRb (Figure 3-1A lane 
2).  Interestingly, E1A Δ26-35 retained the ability to Co-IP GCN5 when both the 12S 
(243R) and 13S (289R) isoforms of E1A were present (Figure 3-1A lane 3).  Moreover, 
while 12S E1A wt and 12S E1A Δ26-35 failed to Co-IP the CR3 specific target MED23, 
the same mutant Co-IPs MED23 when the 13S (289R) isoform is present (Figure 3-1A 
lane 3).  This suggested that there is an interaction between GCN5 and the unique region 
of the largest E1A isoform, which corresponds to CR3 (Figure 3-1A).  Indeed, the CR3 
domain of representative E1As from each hAd species  were sufficient to Co-IP GCN5 
from cells co-transfected with expression vectors for EGFP-fused E1A CR3 and Flag-
tagged mGCN5 (Figure 3-1B). However, the hAd4 E1A CR3 interaction was very weak.  
Using a collection of E1A CR3 mutants, the interaction of GCN5 was mapped to residues 
178-184, since  this mutant failed to IP mGCN5 (Figure 3-1C).  Mutants that have been 
characterized previously to lose interaction with pCAF (Δ139-147), MED23 (H160Y), or 
TBP (V147L) retained interaction with GCN5 (Figure 3-1C) (9, 20, 37, 50).  
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A)  The largest E1A isoform retains a novel interaction site with GCN5.  HeLa cells 
were infected with the indicated viruses at an MOI of 10.  At 24 hours post infection, 
cell lysates were prepared and E1A was immunoprecipitated with M73, separated by 
SDS-PAGE and transferred to PVDF membrane and subsequently probed with anti-
GCN5, anti-pRb, anti-MED23 and anti-E1A antibodies.  B)  All six representative 
E1A-CR3s co-immunoprecipitated mGCN5.  Human HT1080 cells were co-
transfected with expression vectors for myc-EGFP fusions to the indicated E1A-CR3s 
and an expression vector for FLAG-tagged mGCN5.  CR3s were immunoprecipitated 
with anti-myc and probed for GCN5 with anti-Flag.  C) The interaction of E1A-CR3 
with mGCN5 mapped to residues 178-184.  Human HT1080 cells were transfected as 
described above, immunoprecipitated with anti-Flag (for GCN5), separated by SDS-
PAGE, transferred to PVDF membrane and probed with anti-myc (for CR3). 
Figure 3-1: E1A-CR3 Interacts with the KAT GCN5. 
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Furthermore, the interaction of GCN5 with CR3 did not require the zinc finger 
subdomain, because a point mutant in one of the coordinating cysteine residues (C157S) 
and a large deletion encompassing the majority of the zinc finger region (Δ140-160) also 
retained interaction with GCN5 (Figure 1C).  However, mutants that contained deletions 
in the promoter targeting/ATF binding domain lost interaction with GCN5.  Therefore, 
E1A CR3 contains a second independent interaction site for GCN5 that requires at least 
residues 178-184. 
3.3.2 Recruitment of GCN5 to the hAd5 E4 promoter requires both 
the N-terminal and CR3 interaction domains. 
Given the importance of CR3 in activation of viral early gene transcription, we 
hypothesized that the interaction of the largest E1A isoform with GCN5 would be 
involved in this process. This would require GCN5 to be associated with viral promoters 
during infection.  The E4 promoter is potently stimulated by E1A during infection and we 
have shown previously that both E1A and p300 can be found to occupy a 300 bp region 
of this promoter during infection (Figure 3-2A) (38).  In a similar fashion, we determined 
whether GCN5 was recruited to the adenoviral E4 promoter during infection using 
chromatin immunoprecipitation (ChIP).    Indeed, not only was E1A again shown to 
occupy the E4 promoter in cells infected with wt hAd5 (dl309), but GCN5 was also found 
to occupy the E4 promoter in the context of infection (Figure 3-2B).  However, in cells 
infected with a virus lacking E1A (dl312), GCN5 was not found at the E4 promoter. 
Therefore GCN5 associates with the viral E4 promoter in an E1A-dependent manner.  
We tested which of the binding sites on E1A were required to recruit GCN5 to the E4 
promoter using mutant viruses that have a small deletion in either of the two GCN5 
binding sites.  Viruses lacking either residues 26-35 or residues 178-184 showed a 
reduction in recruitment of GCN5 to the E4 promoter, indicating that both sites were 
required by E1A to effectively recruit cellular GCN5 to the viral promoter.  This suggests 
that the two distinct GCN5 binding sites within E1A function in a cooperative manner to 
recruit GCN5 to the E4 promoter (Figure 3-2B). 
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A) Schematic of the right end of the hAd5 genome, showing primer binding sites for 
ChIP PCR.  B) Human A549 cells were infected at an MOI of 5 with the indicated 
viruses (dl309 = wt E1A, dl312 = delta E1A, dl1102 = E1A delta 26-35, dl1114 = 
E1A delta 178-184).  Cells were fixed and chromatin was purified and 
immunoprecipitated with the indicated antibodies.  After washing and de-crosslinking, 
PCR was performed with a set of primers specific for a 320 bp region of the 
adenoviral E4 promoter region. 
 
Figure 3-2: GCN5 Occupies the Adenoviral E4 Promoter During Infection 
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3.3.3 Depletion of GCN5 enhances transactivation by E1A. 
To determine the functional role that GCN5 plays in E1A CR3-dependent transactivation, 
GCN5 was depleted in HeLa cells by specific siRNA (Figure 3-3A), and cells were co-
transfected subsequently with a Gal4-responsive luciferase reporter and an expression 
vector for E1A CR3 fused to the Gal4DBD (Figure 3-3B).  Surprisingly, the 
transactivation function of hAd12, hAd5 and hAd40 E1A CR3 increased in cells treated 
with GCN5 specific siRNA compared to cells treated with control siRNA (Figure 3-3B).  
The transactivation function of hAd4 E1A CR3 was unaffected when GCN5 was 
depleted; this may relate to the fact that the interaction between GCN5 and hAd4 E1A 
CR3 was the weakest of those tested (Figure 3-3-1B).  The ability of hAd3 and hAd9 
E1A CR3 to activate transcription was not significantly increased upon depletion of 
GCN5. These were the two weakest activators of transcription in our panel of E1A CR3s 
(1).  These two CR3s showed an increase in transcriptional activation in GCN5 siRNA-
treated cells compared to control siRNA-treated cells; however, the difference was not 
significant.  The N-terminus of E1A is also capable of activating transcription of a Gal4 
responsive promoter as a Gal4DBD fusion (8) and it also interacts with GCN5 via 
residues 26-35 (26).  However, the transactivation function of the N-terminus of E1A was 
unaffected by GCN5 depletion, suggesting that CR3 is using GCN5 in a fashion distinct 
from the E1A N-terminus (Figure 3-3-3B).  Clearly, GCN5 plays a repressive role in E1A 
CR3-dependent transactivation, because depletion of GCN5 resulted in an overall 
increase in transcriptional activation. 
3.3.4 Overexpression of GCN5 reduces transactivation by E1A. 
If GCN5 is a repressor of E1A CR3-stimulated transcription, it follows that 
overexpression of GCN5 would decrease E1A CR3-dependent transactivation.  To test 
this, we co-transfected human HT1080 cells with a Gal4-responsive luciferase reporter, 
an expression vector for hAd5 E1A CR3 fused to the Gal4DBD and either increasing 
amounts of an expression vector for Flag-tagged mGCN5 (pCMX-FLAG mGCN5) or 
empty vector (pCMX-FLAG) as a control.  The fold activation by Gal4-E1A-CR3 over 
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A) Hela cells were transfected with increasing doses of GCN5-specific siRNA, or 
control siRNA and the levels of GCN5 were determined at 72 hours post-transfection 
by western blot with the indicated antibodies.  B)  HeLa cells were transfected with 20 
nM siRNA specific for GCN5 or control siRNA.  At 48 hrs post-transfection cells 
were split and co-transfected with equal ratios of a (Gal4)6-Luc reporter and an 
expression vector for the indicated Gal4-CR3 fusion.  ‗Vector‘ denotes cells 
transfected with Gal4 alone and N-term denotes cells transfected with and expression 
vector Gal4 fused to residues 1-82 of hAd5 E1A.   At 48 hours post-DNA transfection 
cells were harvested and assayed for luciferase activity.  Fold activation in control vs. 
GCN5 siRNA treated cells were compared by student‘s t test, * indicates P<0.05. 
Figure 3-3:   Depletion of GCN5 results in an Increase in E1A-CR3 Transactivation 
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Gal4 alone, when co-transfected with empty pCMX-Flag was set to 100 %.  Ectopic 
expression of GCN5 resulted in a dose-dependent repression of E1A CR3 transactivation 
(Figure 3-4A).  At the highest dose used (1:1 ratio of pCMX-Flag mGCN5:pM-hAd5 
CR3), a 50 % reduction in E1A CR3 transactivation was observed (Figure 3-4A).  In a 
similar manner, overexpression of GCN5 reduced transactivation of the viral E4 reporter 
by full length E1A by approximately 40 % (Figure 3-4B).  Consistent with the ChIP data, 
mutations in either binding site for GCN5 (deletion of residues 26-35, or 178-184 
respectively) rendered full length E1A significantly less sensitive to overexpression of 
GCN5 (Figure 3-4B).  These data indicate that the repressive effects of GCN5 on 
transactivation by full length E1A required both binding sites to efficiently interact with 
and recruit GCN5 to the E4 promoter. 
3.3.5 Pharmacological inhibition of GCN5 KAT activity enhances 
transactivation by E1A. 
GCN5 was identified originally as a KAT and has a well established role as a 
transcriptional co-activator that acetylates H3K14 to relax chromatin and facilitate 
transcript elongation in the context of the SAGA complex (5, 10, 35, 42).  We 
hypothesized that E1A was retargeting the KAT activity of GCN5 by relocating it to the 
viral template.  Although the viral genome is initially devoid of cellular histones, a recent 
report demonstrates viral core proteins and histones, including H3, bind to viral DNA 
during early phases of infection (25).  Komatsu and colleagues also demonstrated that H3 
is acetylated at K9 and K14 which could be post-translationally modified by GCN5 as a 
consequence of transcription from the viral template; however, no direct role for E1A 
was established.   
Our data suggest that E1A may be utilizing the GCN5 KAT activity to regulate viral 
transactivation.  To test this pharmacologically, we used a novel small molecule that has 
been demonstrated to be a specific inhibitor of GCN5 (14).  The molecule 
cyclopentylidene-[4-(4′-chlorophenyl)thiazol-2-yl)hydrazone (CPTH2) specifically 
inhibits acetylation of histone H3K14 in vitro and in vivo at µM concentrations (14).  We 
first titrated the effect of CPTH2 on hAd5 E1A CR3 transactivation.  Human HT1080 
cells were co-transfected with a Gal4-responsive luciferase reporter and an expression 
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A) Human HT1080 cells were co-transfected with a Gal4-responsive luciferase 
reporter, and expression vectors for a Gal4-fusion and increasing amounts of Flag-
tagged mGCN5.  The fold activation by Gal4-E1A-CR3 over Gal4 alone, when co-
transfected with empty pCMX-Flag was set to 100 %.  INSET:  levels of Flag-tagged 
mGCN5 upon co-transfection of increasing amounts of pMCX-Flag as determined by 
western blot with the indicated antibodies.  B)  Human HT1080 cells were co-
transfected with equal amounts of an adenoviral E4-responsive luciferase reporter, an 
expression vector for E1A, and either empty pCMX-FLAG or pCMX Flag-mGCN5. 
The fold activation of the E4 reporter in cells transfected with wt 13S E1A over empty 
vector, when co-transfected with empty pCMX-Flag was set to 100 %.  Fold activation 
in pCMX-FLAG vs. pCMX FLAG-GCN5 treated cells were compared by students t 
test, * indicates P<0.05. 
Figure 3-4:  Overexpression of GCN5 Results in a Decrease in E1A-CR3 
Transactivation 
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vector for either the Gal4DBD alone or hAd5 E1A CR3 fused to the Gal4DBD.  Cells 
were then treated with either vehicle (DMSO) or a range of concentrations of CPTH2 and 
assayed for luciferase activity 48 hrs post-treatment.  The fold activation by hAd5 E1A 
CR3 over Gal4DBD alone treated with DMSO was set to 100 %.  Treatment of cells with 
CPTH2 resulted in a dose-dependent increase in E1A CR3-stimulated transcription, 
which peaked at a dose of 50 µM CPTH2 and increased E1A dependent activation by 
almost 60 % (Figure 3-5A).  Pharmacological inhibition of the KAT activity mimicked 
RNAi depletion of GCN5, indicating that the KAT activity of GCN5 is required to exert 
the repressive effect on E1A CR3 transactivation.  HT1080 cells co-transfected with an 
E4-responsive luciferase reporter and an expression vector for wt hAd5 E1A (289R) were 
similarly treated with CPTH2, and this also resulted in an increase in transactivation 
compared to vehicle control (Figure 3-5B).  Moreover, mutants lacking either GCN5 
binding site on E1A showed no significant change in transactivation in the presence of 
CPTH2, further demonstrating the necessity of both interaction surfaces for proper 
recruitment and utilization of GCN5 by E1A (Figure 3-5B).   
3.3.6 E4ORF6/7 gene expression is enhanced in cells lacking 
GCN5 KAT activity. 
To test the repressive role of GCN5‘s KAT activity in the context of viral infection we 
used hat/hat MEFs in which both copies of GCN5 were replaced with GCN5 that has a 
point mutant in the catalytic residue of the KAT domain (12).  We measured expression 
levels of hAd5 E4ORF6/7 mRNA during infection by qRT-PCR.  The hat/hat MEFs or 
wt littermate control MEFs were infected at an MOI of 2 with the following hAds: ΔE1A, 
wt E1A, E1A Δ26-35 and E1A Δ178-184.  At 16 hours post-infection there was a 
significant increase in E4ORF6/7 levels in wt hAd5-infected hat/hat MEFs relative to the 
wt littermate control MEFs (Figure 3-6A).  The adenoviruses harboring E1As with 
mutations in either GCN5 binding site showed no significant difference in E4ORF6/7 
levels between hat/hat and control MEFs, indicating that both GCN5 binding sites are 
important for function.  This is consistent with results obtained using the E4 luciferase 
reporter and the small molecule inhibitor CPTH2 (Figure 3-5B Figure 3-6A).  These data 
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A) Human HT1080 cells were co-transfected with a Gal4-responsive luciferase 
reporter and an expression vector for a Gal4-hAd5 CR3 and treated with either DMSO 
or increasing concentrations of the GCN5-specific KAT inhibitor CPTH2. The fold 
activation by Gal4-E1A-CR3 over Gal4 alone, when treated with DMSO (vehicle) was 
set to 100 %. B)  Human HT1080 cells were co-transfected with an adenoviral E4 
responsive luciferase reporter and with the indicated expression vector for E1A, and 
treated with either DMSO or 50 μM CPTH2. The fold activation of the E4 reporter in 
cells transfected with wt 13S E1A over empty vector, when treated with DMSO 
(vehicle) was set to 100 %.  Fold activation in DMSO-vs. CPTH2-treated cells were 
compared by students t test, * indicates P<0.05. 
Figure 3-5:  Inhibition of GCN5 HAT-Activity Mimics Depletion of GCN5 
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A) Either hat/hat or wt littermate control MEFs were infected with the indicated 
viruses at an MOI of 2.  At 16 hours post-infection total RNA was collected and the 
level of E4ORF6/7 mRNA relative to E1A mRNA and GAPDH mRNA was 
determined by qRT-PCR.  Mean relative E4ORF6/7 expression between hat/hat and 
wt littermate control MEFs were compared by students t Test, * indicates P< 0.01.  B)  
Human A549 cells were infected with wt hAd5 at an MOI of 5 and subsequently 
treated with either DMSO or 50 μM CPTH2.   At 96 hours post-infection cells were 
harvested and virus yield was determined by plaque assay on HEK293 cells.  Mean 
virus yield in PFUs/ml were compared by students t test, * indicates P<0.05. 
Figure 3-6: The KAT Activity of GCN5 Modulates E1A function During Infection. 
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further support a model in which E1A uses the KAT activity of GCN5 to repress 
transactivation of the viral E4 promoter in the context of infection.   
3.3.7 Inhibition of GCN5 KAT activity reduces virus growth. 
The results described above suggested that E1A has evolved to utilize GCN5 as a 
repressor to fine-tune transactivation of the early viral promoters in order to generate and 
maintain an optimal environment for virus replication.  We determined the consequence 
of blocking GCN5 KAT activity on virus replication in permissive cells.  Human A549 
cells, the diagnostic cell line for hAd isolation and analysis, were infected at an MOI of 5 
with wt hAd5 and treated with either vehicle (DMSO) or 50 µM CPTH2.  At 96 hours 
post-infection, cells were harvested, freeze-thawed three times and virus titer was 
determined on HEK293 cells.  Chemical inhibition of the KAT activity of GCN5 resulted 
in a near 1 log unit reduction in virus growth at 50 µM CPTH2 (Figure 3-6B).  These data 
demonstrate that the KAT activity of GCN5 is required for optimal virus growth, and 
support a model in which E1A transactivation must be tightly regulated by both co-
activators and repressors in order to maximize virus growth.  
3.4 Discussion 
The CR3 portion of hAd5 E1A is a potent transcriptional activation module and serves as 
a paradigm of viral transactivation (6, 18, 36).  CR3 is the most highly conserved of the 
four conserved regions within E1A, yet there are dramatic differences in the potency of 
the CR3 domains from six representative E1As with respect to transactivation (1).  The 
differences in transactivation ability of these representative E1A CR3s was shown to be 
independent of the conserved co-activators of E1A CR3: MED23, TBP, SUG1 and 
p300/CBP (1).  Moreover, competition experiments suggested that additional cellular 
factors were involved in E1A CR3 transactivation that may include negative regulators 
(1).  We report here the identification of a second interaction surface in E1A CR3 for the 
cellular KAT GCN5, and our experiments identify GCN5 as a novel negative regulator of 
E1A transactivation.    
The interaction of GCN5 with the N-terminus of E1A had been reported previously, but 
all of the experiments used mutant hAds that could only synthesize the 12S (243R) 
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isoform of E1A and thus did not contain CR3 (26).  We repeated the interaction 
experiment using a virus with the same mutation, i.e, deletion of  residues 26-35 of E1A 
we showed that in the context of the 13S (289R) E1A protein, which contains CR3, a 
virus with the Δ26-35 mutation in E1A retained interaction with GCN5 (Figure 3-1A).  
Importantly, it has been established that the E1A of viruses with this Δ26-35 mutation 
retain interaction with the other cellular proteins shown to interact with the N-terminus of 
E1A namely, pRb, pCAF and p300 (16, 26, 37, 40).  The interaction profile of MED23 
with these E1A mutants was also examined as a control for binding of CR3-specific 
interactors (Figure 3-1A).  MED23 is only co-immunoprecipitated with the largest 
isoform of E1A (289R in hAd5), i.e., when CR3 is present, consistent with previous 
reports that indicate MED23 only interacts with the largest E1A isoforms (1, 9, 47).  
Furthermore, the interaction of GCN5 with CR3 was conserved across all six hAd 
species, suggesting that the functional role of GCN5 is also conserved (Figure 3-1B).  
The GCN5 interaction site within CR3 was mapped to residues 178-184, which excludes 
the residues required for interaction with SUG1 (Figure 3-1C) (39).  The promoter 
targeting domain of E1A CR3 was originally shown to be residues 183-188, which does 
overlap this newly identified GCN5 binding site (20, 28, 50).  However, we have shown 
here that E1A Δ178-184 is still recruited to the E4 promoter (Figure 3-2B). 
There is a dichotomy of conservation at the primary amino acid level among hAds in the 
region required for GCN5 interaction.  Residues 174 to 181 of E1A are very poorly 
conserved among the six representative hAds in our panel (1, 4).  However, between 
residues 182 and 184 there is a much greater degree of conservation.  Of the six 
representative E1As, CR3s from species A through D share a conserved phenylalanine 
residue at position 182, while species E and F, including hAd4 which binds GCN5 
poorly, have a cysteine residue that may contribute to the poor interaction of GCN5 with 
hAd4 CR3.  Residues 183 and 184 are very highly conserved among E1As.  Residue 183 
is either a valine or isoleucine and residue 184 is an invariant tyrosine residue.  These 
latter conserved residues may make key contacts between GCN5 and E1A CR3.  
The primary function of the largest E1A proteins is to activate early viral gene expression 
by recruiting the cellular transcription machinery to the early viral promoters (6, 18, 36).  
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Thus, GCN5 would be expected to be present at the viral promoter with E1A, and indeed 
GCN5 is associated with the viral E4 promoter in an E1A-dependent manner (Figure 3-
2B).  Interestingly, the recruitment of GCN5 to the E4 promoter requires both GCN5 
binding sites in E1A, demonstrating for the first time a physical cooperation between the 
N-terminus of E1A and CR3 to recruit a cellular protein to the promoter (Figure 3-2B).  
There is a large body of evidence to suggest that both the N-terminus of E1A and CR3 
are transactivation domains. Yet there is very little evidence demonstrating that the N-
terminus of E1A and CR3 can cooperate to interact with and recruit cellular proteins (52).  
Several cellular proteins that bind to CR3 also interact with the N-terminal CR1 domain 
of E1A including TBP, pCAF, Sug1, and p300/CBP (27, 37-39).  There is also evidence 
that the N-terminus of E1A and CR3 could cooperate functionally.  For example, both 
regions can activate transcription when fused to a heterologous DBD (6, 18, 36), and 
CR3 can synergize with the N-terminus to activate the E2 promoter, presumably via 
recruitment of TBP and sequestration of pRb (52).  In essence, the interaction of GCN5 
with two distinct regions of E1A provides a satisfying mechanism to explain the 
historical observation that both these regions of E1A are required for efficient activation 
of early gene expression (46, 52).     
RNAi depletion of GCN5 resulted in an increase in E1A CR3 transactivation and 
provided the first indication that GCN5 is a true negative regulator of E1A transactivation 
(Figure 3-3B).  This role of GCN5 as a negative regulator was conserved among our 
panel of representative CR3s of each hAd species with the exception of hAd4 E1A CR3 
(species D), which also had the weakest physical interaction with GCN5 (Figure 3-3B).  
Perhaps hAd4 E1A CR3 does not require the same level of negative regulation that the 
other CR3s display as a consequence of its weaker intrinsic activation function.  
Depletion of GCN5 resulted in an increase in transcriptional activation (Figure 3-3B), 
whereas depletion of the other cellular factors required by CR3 (MED23, p300 SUG1 or 
pCAF) results in a decrease in transactivation (1).  This gain of function phenotype 
suggests that GCN5 is part of another layer of transcriptional control that is recruited to 
promoters by E1A to optimize early gene expression.  This is a rare example where 
removing a cellular binding partner of CR3 results in enhanced E1A transactivation.  The 
same phenotype has been demonstrated before by depleting CtBP by siRNA or 
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sequestering CtBP with the C-terminus of E1A (11).  In the context of infection, such a 
paradigm makes complete sense since many of the gene products of the E4 region are 
toxic and stimulate cellular defenses and/or antagonize survival pathways (45, 51).  
Therefore it appears that E1A utilizes GCN5 to help balance transactivation of the E4 
promoter.  Similarly, there may need to be regulated expression of the E1B, E2 and E3 
promoters as well. 
If GCN5 negatively regulates E1A CR3-dependent transactivation, then ectopic 
expression of GCN5 should exacerbate the negative effect on CR3 transactivation.  This 
was indeed the case, since overexpression of GCN5 resulted in a decrease in 
transactivation by CR3 fused to a heterologous DBD, and also by full length E1A acting 
on an E4 responsive reporter (Figure 3-4).  The effect of GCN5 again highlights the 
cooperative nature of the GCN5 interaction, because mutation of either binding site 
rendered E1A non-responsive to the repressive effects of GCN5 (Figure 3-4).  GCN5 is 
apparently a limiting factor in this process, since the endogenous levels within cells do 
not allow for maximal repression (Figure 3-4).  Both of these observations suggest that 
GCN5 is required in stoichiometric, rather than catalytic, amounts to exert its negative 
effects.   
GCN5 is ascribed to have two catalytic functions in the SAGA complexes of both yeast 
and mammalian cells, a KAT activity and a deubiquitinating activity (5, 10, 35, 42).  Our 
results indicate that the KAT activity of GCN5 is required to negatively affect E1A 
transactivation on both plasmid and viral genomic templates (Figure 3-5 Figure 3-6A).  
This is the opposite effect reported for GCN5 on chromatin templates, where acetylation 
is usually correlated with transcriptional activation (5, 10, 19, 35, 42).  The hAd genome 
has been shown to associate with cellular histones including H3, which is acetylated at 
K9 and K14, presumably by GCN5 (25), yet no direct role for E1A in this process has 
been demonstrated.  Thus it is possible that E1A is co-opting GCN5 for an alternative 
purpose.  However, there is a single report that links the KAT activity of GCN5 and E1A 
transactivation that requires the Mediator complex.  A sub-Mediator complex, referred to 
as T/G Mediator, exists that includes MED23, the kinase CDK8 and GCN5 (32).  This 
complex is responsible for histone H3 S10/K14 tandem phosphoacetylation; the KAT 
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activity of GCN5 and the kinase activity of CDK8 are catalytically responsible for the 
tandem phosphoacetylation event in vivo, which leads to transcriptional activation (32).   
GCN5 interacts with E1A via its N-terminus, MED23 binds through CR3 and we now 
show that GCN5 independently binds CR3 (Figure 3-1) (26). Therefore, it is entirely 
possible that E1A could also recruit the kinase activity of CDK8 to CR3 via MED23 or 
GCN5.  Interestingly, within CR3 two serine residues (S185 and S188) are critical to 
E1A transactivation and they are hyperphosphorylated in vivo (51).  S185, but not S188 
was reported to be phosphorylated by MAPK (51).  S188 is found in a CDK8 consensus 
phosphorylation site (41).  Indeed the sequence found in E1A, YSPVS, is very similar to 
the consensus sequence of the RNA PolII C-terminal domain (YSPTSPS) which is also 
phosphorylated by CDK8 in the context of Mediator (41).  Therefore the missing link 
required for phosphorylation of S188, a modification known to affect E4 transactivation, 
may be the T/G Mediator complex (32, 51).     
Importantly, pharmacological inhibition of GCN5 reduced virus yield, suggesting that a 
balanced level of E1A transactivation is required for optimal virus growth (Figure 3-6B).  
This same inhibition of GCN5 KAT activity coincides with an increase in E4 promoter 
activity (Figure 3-6A).  Increased transcription of the E4 promoter is known to enhance 
premature killing of infected cells (51).  The adenoviral E4 promoter appears to have 
redundant levels of regulation.  Not only does GCN5 appear to  limit E4 promoter 
activity, but the E4 transcription unit also encodes the E4ORF4 protein, which interacts 
with cellular PP2A to dephosphorylate S188 of E1A, completing a negative feedback 
loop for E1A transactivation (51).  Therefore the negative effect of GCN5 on E1A-
dependent transactivation may provide the optimal intracellular milieu for virus 
replication by initially maximizing expression of the E4 transcription program needed for 
the viral replication cycle, then minimizing the transcription of potentially hazardous 
viral proteins via the E4ORF4 negative feedback loop. 
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Chapter 4  
4 The Structure of E1A CR3 
Despite exhaustive efforts using mutants, a detailed structure-function relationship of 
E1A CR3 transactivation remains elusive. To date no high resolution structural 
information is available for E1A CR3.  In this chapter I will review the evidence 
suggesting that CR3 likely has a well defined structure, and I demonstrate experimentally 
that E1A CR3 is indeed a highly ordered and structured domain. 
4.1 Background and Literature Review 
The very earliest experiments that implicated CR3 in transactivation also hinted at the 
structured nature of the domain.  Host range (hr) in hAd5 was originally defined as the 
ratio between virus growth on 293 cells, which express E1A and E1B, versus HeLa cells 
which do not express E1A and E1B (21).  All group I hr mutants are unable to synthesize 
early viral mRNAs in HeLa cells, but can be rescued on 293 cells, and the mutations map 
to residues in E1A CR3 (7, 15).  Eventually, the group I hr mutants were shown to be 
single aa substitutions in key residues of E1A CR3 (19).  Thus, unlike the remainder of 
E1A, substitution of a single aa in CR3 is enough to abolish early gene activation and 
ultimately virus growth, suggesting that the mechanism of CR3-dependent transactivation 
is distinct from other E1A functions.  One interpretation of this critical difference 
between CR3 function and other functions of E1A is that a complex tertiary structure is 
required for CR3 function.  If CR3 maintained a well defined structure, then mutations in 
key residues making intra-molecular contacts would result in a phenotype similar to the 
hr mutants. 
The classical approach to deciphering E1A function was based on numerous E1A 
deletion mutants, and these mutants were instrumental in understanding most functions of 
E1A including oncogenic transformation.  The majority of E1A tolerates deletions well, 
such that small deletions affect interaction with only a subset of binding partners without 
negating E1A function globally (14, 30).  This led to a model of the 12S E1A product 
being a string of protein-protein interaction motifs.  In contrast, CR3, found in the 13S 
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E1A product, is unique in that all deletion mutants within this region fail to activate 
transcription, again indicating that CR3 is quite different from the rest of E1A (22).  Only 
when an alternative approach to mutational analysis involving single conservative 
substitutions was employed was insight into the structure-function relationship of CR3 
revealed. 
Analysis of the primary amino acid sequence of E1A CR3 revealed two CXXC motifs 
which are indicative of a C4 zinc finger domain.  These four cysteines residues (C154, 
C157, C171 and C174) were later shown to coordinate a single zinc ion and are 
absolutely required for E1A CR3 transactivation (10, 39).  Interestingly, none of the 
group I hr mutants were point mutations in the coordinating cysteine residues (19).  
Comprehensive mutational analysis of CR3, where every residue from 140 to 188 was 
individually substituted to a conservative amino acid, only solidified the view the E1A 
CR3 is structured (18, 39).  Even very subtle conservative changes in select CR3 residues 
resulted in dramatic loss in transactivation function (18, 39).   
The most striking evidence suggesting that CR3 is structured comes from an in-depth 
analysis of E1A primary sequence.  As a whole, the primary amino acid sequence of the 
243 E1A is densely packed with short linear interaction motifs or SLIMs (30).  In some 
cases the interaction motifs actually overlap, for example the DLX in the pRb DLXCXE 
SLIM, corresponds to the DLT sequence in the SUMO EVIDLT SLIM (30, 41).  
Analysis of the 289R E1A of hAd5, which includes CR3, demonstrates that with the 
exception of the putative nuclear localization signal (NLS) reported in CR3, this region of 
E1A is completely devoid of SLIMS; yet CR3 interacts with an equally impressive 
collection of cellular proteins (30, 35, 36). The non-conventional and developmentally 
regulated NLS (FV(X)7–20MXSLXYM(X)4MF) reported in CR3 spans residues 140-185.  
This putative NLS encompasses the entire zinc finger subdomain of E1A CR3.  
Furthermore, the region spanning residues 140-185 is required for interaction with at 
least three cellular proteins found in the nucleus (TBP, MED23 and pCAF), which could 
also mediate the nuclear localization of CR3 (9, 12, 24, 31).  I hypothesize this lack of 
SLIMs and the complexity and features of the NLS in CR3 are indicative of a complex 
CR3 secondary and/or tertiary structure that would generate non-linear interaction motifs.  
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Taken together, the literature and sequence of E1A demonstrate that CR3 is not only very 
different from the rest of E1A in terms of overall function, but also with respect to 
sequence conservation, distribution of SLIMs and sensitivity to deletion mutations.  
These observations of E1A CR3‘s distinct characteristics suggest that unlike the 
remainder of E1A, this region exhibits a complex secondary and/or tertiary structure to 
organize cellular transcription factors spatially and temporally to ultimately achieve its 
unique function of activating early viral genes. 
4.2 Materials and Methods 
4.2.1 Prokaryotic and Mammalian Cells 
Human A549 lung adenocarcinoma cells were a maintained in DMEM containing 10 % 
FBS 100 U/ml penicillin/streptomycin and grown at 37 °C and 5 % CO2.  Prokaryotic E. 
coli strain DH5-alpha was used to maintain all plasmids while, E. coli strain BL-21 RIL 
(Stratagene) or BL-21 plysys (Novagen) were used for protein production and maintained 
on 68 µg/ml of chloramphenicol (CAM) (Bioshop). 
4.2.2 Plasmid Construction 
The prokaryotic expression vector pGEX4T1-TEV was constructed by annealing 10 ng 
each of two oligos (5`-AATTAGAGAATTTGTATTTTCAGTCTGGAG-3` and 5`-
AATTCTCCAGACTGAAAATACAAATTCTCT-3`) at 100 °C in ddH2O for 10 minutes 
followed by slowly cooling to room temperature.  The parent vector pGEX4T1 
(Clontech) was cut with EcoRI (New England Biolabs, NEB), the annealed oligo was 
ligated into the EcoRI site using T4 DNA ligase (NEB), transformed into competent E. 
coli strain DH5α and selected on 200 µg/ml ampicillin (AMP) (BioShop).  Clones were 
screened by sequencing, and a clone that had only one copy of the oligo inserted was 
chosen for further manipulation.  To generate pGEX4T1-TEV-Ad5 CR3, the DNA 
sequence encoding hAd5 E1A CR3 residues 139-204 was cut from pM-Ad5 CR3 (34) 
with EcoRI and NotI and ligated to the same sites of pGEX4T1-TEV.  Correct clones 
were verified by sequencing.  The truncations of hAd5 E1A CR3 at residues 190 
(pGEX4T1-TEV-Ad5 CR3 190T) and 178 (pGEX4T1-TEV-Ad5 CR3 178T) were 
generated by PCR using a common forward primer (5`-
102 
 
AGACGAATTCGGTGAGGAGTTTGTGTTA-3`) and reverse primers CR3190T-R (5`-
CTGTCGACTTAAGGTTCAGACACAGGACT-3`) and CR3178T-R (5`-
GATGGATCCTTAGGTCCTCATATAGCAAA-3`), respectively with Phusion 
polymerase (NEB) according to the manufacturer‘s directions.  PCR products were cut 
with the same enzymes described above and cloned into the same sites used for 
pGEX4T1-TEV-Ad5 CR3. 
4.2.3 Production and Purification of CR3 for NMR Analysis 
The expression vectors described above were transformed into E. coli strain BL-21 RIL 
(Stratagene) or BL-21 plysys (Stratagene) and selected on 200 µg/ml AMP and 68 µg/ml 
of CAM.  Individual colonies were selected and grown in LB broth containing AMP and 
CAM overnight.  Overnight cultures were pelleted, washed once in PBS, and then diluted 
to a starting OD600 of 0.2 in M9 media (42 mM Na2HPO4, 24 mM KH2PO4, 9 mM NaCl, 
19 mM NH4Cl, 1 mM MgSO4 , 0.1 mM CaCl2 , 0.3 % glucose,  10 µg/ml thiamine, 10 
µg/ml biotin, 50 µg/ml carbenicillin and 34 µg/ml (CAM) and supplemented with 20 µM 
ZnCl2.  Cultures were grown at 37 °C at 250 rpm until a OD600 of ~0.9 was reached (mid-
log phase), at which point cultures were induced with 1 mM IPTG (Bioshop) and 
transferred to 16 °C for 18 hours.  Cells were harvested by centrifugation (5000 x g for 
10 minutes at 4 °C) and lysed in 10 ml of Lysis Buffer (1x PBS pH 7.4, 0.2 % Tween-20, 
2 mM DTT and 1.0 mg/ml lysozyme) per gram wet weight of the pellet.  The pH of 
resuspended pellets was raised to 8.15 with 1 M Tris pH 11.0 and incubated at 37 °C for 
10 minutes.  Lysates were then sonicated for three cycles of 20 seconds at max power 
with a microtip sonicator (VWR).  Lysates were clarified by centrifugation at 30 000xg 
for 30 minutes at 4 °C.  The soluble fraction was collected and the pH adjusted to 7.2 
with concentrated HCl.  Glutathione S-transferase (GST)-fused proteins were recovered 
by the addition of 6 ml of 50 % slurry of glutathione sepharose (GE) and incubated at 
room temperature for two hours with nutating.  Glutathione sepharose was washed with 
100 column volumes of lysis buffer without lysozyme (~300 ml).  CR3 was liberated 
from GST while bound to glutathione sepharose by the addition of a 4000:1 ratio of GST-
protein: TEV protease in lysis buffer.  TEV cleavage was performed at 4 °C with nutating 
overnight (minimum 16 hours).  The soluble fraction now containing liberated CR3 was 
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collected and diluted 10 fold in start buffer (20 mM Tris pH 7.8 + 2 mM DTT) and 
pumped onto a HiTrapQ FF anion exchange column with a syringe.  The column was 
then connected to an Akta FPLC purifier and CR3 was eluted with a linear salt gradient 
from 0-100 % of elution buffer (20 mM Tris pH 7.8, 2 mM DTT, 1 M NaCl).  CR3 eluted 
at approximately 40 % NaCl, and fractions were collected and dialyzed into FPLC buffer 
(20 mM Tris pH 7.8, 2 mM DTT, 150 mM NaCl) and concentrated to a 400 µl volume.  
The concentrated CR3 was loaded onto a Superdex75 column and separated by gel 
filtration chromatography (GFC).  The peak corresponding to CR3 was collected and 
dialysed into 50 mM HEPES buffer pH 6.5 plus 2 mM DTT for NMR analysis. 
4.2.4 Mass Spectrometry Quality Control of Purified CR3  
5 % of the recombinant CR3 purified for NMR analysis (ranging from 500 to 1000 
pmoles depending on the protein sample) was sent to the UWO Biological Mass 
Spectrometry Facility for mass determination.   
For mass determination of CR3 residues 139-204 under denaturing conditions, the sample 
was treated with 50 % acetonitrile.  Mass spectrometry was performed on a QTof Micro 
mass spectrometer (Micromass) equipped with a Z-spray source and run in positive ion 
mode.  Cone voltage was 50 V and a source temperature of 80 °C was used.  Calibration 
was performed with myoglobin with mass error of less than 0.5 Da.  Data was acquired 
using MassLynx 4.1 (Micromass) acquisition software.  For mass determination of CR3 
190T (residues 139-190 of hAd5 E1A) under non-denaturing conditions, the samples 
were diluted 10 fold in 10mM ammonium acetate.  Mass determination under denaturing 
conditions was performed in 50 % acetonitrile as above but with variable cone voltage. 
4.2.5 Med23 Competition Assay for Quality Control of Purified 
CR3 
Human A549 cell lysate was prepared by lysis in 5 packed cell volumes of E1A buffer 
(29) containing protease inhibitors (Sigma) on ice for 10 minutes followed by 
clarification at 20 000 x g for 10 minutes at 4 °C.  One mg of A549 total cell lysate was 
mixed with 1 µg of purified GST or GST-hAd5 CR3 and 20 µl of 50 % glutathione 
sepharose and incubated at 4 °C for 60 minutes with nutating.  Glutathione sepharose was 
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collected by centrifugation, washed three times with E1A buffer containing protease 
inhibitors and finally resuspended in 1 ml of E1A buffer with protease inhibitors 
followed by the addition of increasing amounts of purified CR3.  GST alone was treated 
with the maximum amount of CR3 and incubated for an additional 60 minutes at 4 °C 
with nutating.  Glutathione sepharose was again collected by centrifugation and washed 
once with E1A buffer containing protease inhibitors.  Samples were resuspended in 1x 
protein loading dye and 1 mM DTT and boiled at 100 °C for 10 minutes.  Samples were 
separated by SDS PAGE, transferred to PVDF membrane and immunobloted as 
described above in section 2.2.4 with a primary antibody to human MED23 (NOVUS) at 
a dilution of 1:2000.  Input amounts of GST, GST-hAd5 CR3 and purified CR3 were 
detected by Ponceau stain (Sigma). 
4.2.6 NMR Data Collection 
Purified CR3 139-204 at a final concentration of 100 µM in 50 mM HEPES pH 6.5 was 
used to collect 2-Dimensional heteronuclear single quantum correlation (2D HSQC) 
spectra.    Experiments were performed on a Varian Inova 600 MHz spectrometer 
equipped with a xyz-gradient triple resonance probe (UWO Biomolecular NMR Facility).  
The spectrum was acquired for 8 hours at 25 °C. All chemical shifts were referenced to 
the internal DSS (2,2-dimethyl-2-silapentane-5-sulfonate) signal. Data were processed 
and analyzed using the programs NMRPipe (11) and NMRView (23).  Purified CR3 139-
190 at a final concentration of 50 µM was used to collect a 2D HSQC spectrum as 
described above.  The 2D HSQC spectrum was acquired for 18 hours at 25 °C.  For 
EDTA chelation of zinc, purified CR3 190T at a final concentration of 100 µM was used 
to collect a 2D HSQC of CR3.   The same sample was subsequently treated with 500 µM 
EDTA to chelate zinc ions from CR3 and the spectrum was collected under the same 
conditions.  Both spectra were collected for 21 hours at 25 °C 
4.3 Results 
4.3.1 In silico Analysis of E1A Order versus Disorder 
I hypothesized that E1A-CR3 was structured or highly ordered, and that this property was 
unique to CR3 relative to the remainder of E1A.  Thus I employed a bioinformatic tool to 
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analyze the propensity of order versus disorder in E1A.  The software tool, Predictor of 
Naturally Disordered Regions (PONDR), breaks a given amino acid sequence into 9-21 
amino acid windows and then takes into account parameters such as net charge and 
hydropathy index and subsequently assigns each window of the amino acid sequence a 
score between 0 and 1.  A score of 1 indicates a disordered region while a score of 0 
indicates order.  The threshold value is set to 0.5, so effectively a score above 0.5 is 
disordered and a score below 0.5 is ordered.  The further the score differs from 0.5, the 
more likely the prediction is correct (1).  I put the primary amino acid sequence of hAd5 
289R E1A into PONDR and the output is shown in figure 4-1.  PONDR clearly predicts 
an ordered region of E1A that peaks between residues 150 and 175.  This region 
corresponds to the C4 Zinc finger subdomain of CR3, which is bound by coordinating 
cysteines at residues 154 and 174 (Figure 4-1).  PONDR also predicts a disordered region 
adjacent to CR3 that corresponds to the promoter targeting subdomain of E1A CR3 
thought to make promiscuous interactions with cellular DNA-binding transcription 
factors (Figure 4-1).  Therefore PONDR supports the suggestion that there are two 
functional subdomains of E1A CR3 and that these regions, which appear to have very 
different propensities to form stable structures, work together to locate a functional 
transcription initation complex to large variety of promoters. 
Apart from the zinc finger domain of CR3, the only other region of E1A predicted to be 
ordered is the extreme N-terminus and this property is also predicted to be shared by E1A 
proteins from all six hAd speciess (4, 16, 30).  This feature at the extreme N-terminus of 
E1A is thought to be critical to interacting with and organizing the numerous cellular 
proteins that interact with this region of E1A (30).  In the case of hAd5 E1A this putative 
alpha helix is predicted to have amphipathic characteristics based on its unique "corner 
box" motif and the involvement of three leucine residues that when mutated affect 
binding to multiple cellular partners (8, 30, 32).  Curiously, both the N-terminus and CR3 
were predicted by PONDR to be ordered, and both share a common theme where single 
point mutations have been shown to disrupt interaction with multiple cellular binding 
partners and have dramatic effects on their respective functions. 
106 
 
Figure 4-1 In silico Prediction of Ordered and Disordered Regions of hAd5 E1A 
The amino acid sequence of 289R E1A was submitted to PONDR.com for in silico 
prediction of ordered versus disordered regions within E1A and the output is shown.  
The X-axis depicts the residues of E1A and the Y-axis plots a measure of 
ordered/disordred state, VL-XT.  The threshold value is set to 0.5; above this value a 
region is predicted to be disordred, and a value below 0.5 predicts an ordered or 
structured region.  There is a clear region of predicted order between residues 150 to 
175 that corresponds to the zinc finger binding subdomain of E1A CR3. 
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PONDR, predicted the disordered regions of E1A consistent with other findings and 
predictions.  It also supports my hypothesis by predicting that the zinc finger subdomain 
of E1A CR3 is structured.  Based on this in silico confirmation, I proceeded to determine 
the three dimensional structure of the hAd5 E1A transactivation domain within CR3.  
Due to the relatively small size of the CR3 domain, whose maximum size would be 65 
amino acids, and given the expertise and equipment available in the department of 
Biochemistry at the University of Western Ontario, I chose to pursue the structure of E1A 
CR3 by nuclear magnetic resonance (NMR) spectroscopy. 
4.3.2 Construction of a Prokaryotic Expression Vector for E1A-
CR3 
Previous studies in Dr. Mymryk's laboratory has successfully expressed E1A and 
fragments of E1A as GST fusions (5, 31, 33, 34).  In order to produce sufficient 
quantities of the CR3 domain of hAd5 E1A free of any affinity tags, I created a 
prokaryotic expression vector for GST fusions that integrated a tobacco etch virus (TEV) 
protease cleavage site between GST and CR3.  I designed DNA oligonucleotides that 
when annealed to each other would base pair to the cleaved EcoRI site of pGEX4T1 
(Figure 4-2A) and add the desired sequences.  Upon integration of a single copy of the 
annealed oligonucleotides into EcoRI digested pGEX4T1, the upstream EcoRI site was 
destroyed and followed by codons for the optimized TEV cleavage site ENLYFQS 
(Figure 4-2B).  These codons were followed by a single glycine codon and finally the 
EcoRI site was regenerated downstream such that CR3 could be cloned in with EcoRI, in 
frame with GST and the TEV cleavage site (Figure 4-2B).  The newly generated 
prokaryotic expression vector was called pGEX4T1-TEV and was verified by 
sequencing.  The entire CR3 domain of hAd5 E1A encompassing residues 139-204 was 
cloned into pGEX4T1-TEV with EcoRI and NotI sites and verified by sequencing.  GST-
fused E1A CR3 was then produced in BL-21 plysys E. coli and purified with glutathione 
sepharose.  Treatment of the purified GST-E1A-CR3 with TEV protease resulted in the 
liberation of E1A-CR3 from GST, while a control sample without TEV protease showed 
no cleavage (Figure 4-2C). 
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Figure 4-2  Features and Characteristics of pGEX4T1-TEV 
A) Vector map of pGEX4T1-TEV. GST and AMP open reading frames are indicated as 
red arrows.  The TEV cleavage site is located between the BamHI and EcoRI restriction 
sites.  B)  Sequence of the MCS of pGEX4T1-TEV.  The TEV recognition site (shaded 
black) is shown translated and is in frame with the GST open reading frame upstream 
(shaded grey) and the EcoRI site downstream (shaded grey).  The NotI site is denoted in 
italics and is underlined.  C) The expression vector pGEX4T1-TEV-Ad5 CR3 was 
transformed into BL-21 E. coli and expression induced by the addition of IPTG.  The 
GST fusion was purified with glutathione sepharose affinity resin.  The washed resin 
was incubated with or without TEV protease.  Samples were separated by SDS PAGE 
and stained with coomassie blue.  Bands corresponding to GST-CR3, GST alone, or 
CR3 alone are indicated. 
A 
GST-CR3
GST
CR3
- +
TEV
C 
pGEX4T1-TEV 
4999bp 
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4.3.3 Production and Purification of E1A-CR3 for NMR Analysis 
In order to resolve structural information from purified E1A CR3 by NMR the protein 
must be isotopically labeled to ensure 
1
H, 
15
N and 
13
C atomic nuclei have angular 
momentum values equal to ½, i.e. an odd number of neutrons.  Therefore a strain of BL-
21 pLsys E. coli harboring pGEX4T1-TEV-CR3 was grown in M9 minimal media with 
15
N-ammomium chloride as the sole nitrogen source and/or 
13
C-glucose as the sole 
carbon source.  Labeled CR3 was purified with the optimized purification strategy 
outlined in Figure 4-3.  Briefly, cells were collected by centrifugation at 18 hrs post 
induction and lysed in lysis buffer containing 1 mg/ml lysozyme, then sonicated and 
GST-CR3 was purified by the addition of glutathione sepharose to clarified lysates.  
Glutathione sepharose was washed extensively and CR3 was liberated directly from the 
resin by addition of TEV protease.  Liberated CR3 was then concentrated by Ion 
Exchange Chromatography (IEC) using HiTRAPPQ anion exchange resin.  CR3 was 
eluted with a linear linear salt gradient, and it eluted at 40 % NaCl.  The peak 
corresponding to CR3 was collected and dialyzed to remove excess salt and then 
separated by Gel-Filtration Chromatography (GFC) using either Sephadex 75 or 
Sephadex 200 resin, which separated the small CR3 peptide from larger contaminating 
proteins (Figure 4-3).  The final product was verified by mass spectrometry. 
4.3.4 Quality Control of Purified CR3 Residues 139-204 
The quality of purified CR3 was verified by mass spectrometry and also assessed 
functionally using a binding assay with a known cellular binding partner.   The 
theoretical calculated mass for the unlabeled 70 amino acid peptide corresponding to 
residues of 139-204 of hAd5 E1A is 7960.80 Da (2).  The experimental mass of 
unlabeled CR3 139-204 obtained was 7959.32 Da.  Therefore, the CR3 produced was of 
the appropriate mass and appeared stable because no apparent degradation products were 
seen (Figure 4-4). 
To functionally assess the quality of the purified full length CR3, I developed a 
competition assay to determine if purified CR3 could compete with GST-CR3 for binding 
to the well established cellular binding partner MED23 (9, 37).  Interaction with MED23 
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Figure 4-3 Purification Scheme of E1A-CR3 
GST-CR3 was grown in E. coli Strain BL-21 plysys, bacterial cells were collected subsequently 
and lysed in lysis buffer.  GST-CR3 was then collect with GST affinity resin (glutathione 
sepharose) and washed extensively.  CR3 was then liberated from GST by the addition of TEV 
protease directly to the GST-affinity resin.  Liberated CR3 was concentrated by ion exchange 
chromatography (IEC) and eluted with high salt.  The eluted CR3 was then dialysed to remove 
excess salt and further purified by gel filtration chromatography (GFC).  
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Figure 4-4 Mass Determination of Purified CR3 Residues 139-204 
Purified CR3 peptide consisting of residues 139-204 of hAd5 E1A was analyzed by 
MALDI-TOF mass spectrometry by the University of Western Ontario Biological 
Mass Spectrometry Laboratory.  The observed of CR3 139-204 was 7959.91 Da, 
consistent with the predicted mass of 7960.8 Da.  
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requires properly folded E1A CR3 (9). While GST alone failed to interact with MED23, 
GST-CR3 interacted with and pulled down MED23 from A549 cell lysate (Figure 4-5).  
Using a fixed amount of GST-CR3 and titrating in the purified CR3, I observed a dose 
dependent loss of interaction of GST-CR3 with MED23.  Therefore, the purified CR3 
could interact with MED23 and was likely folded properly, since the interaction of 
MED23 and E1A requires an intact zinc finger subdomain of CR3 (9, 37).  There was an 
accumulation of GST that appeared with increasing amounts of purified CR3, which was 
the result of contaminating GST in the purified CR3 preparation that was recovered due 
to an excess of glutathione sepharose in the reaction. 
4.3.5 Two Dimensional HSQC of CR3 Residues 139-204 
Satisfied that the purified CR3 was folded properly based on the quality control 
experiments, I proceeded to acquire a 2D HSQC spectrum and determine experimentally 
if CR3 is structured.  CR3 was overexpressed in E. coli using M9 minimal media 
containing 
15
N-NH4Cl and purified as described above.  Labeling all of the nitrogen 
atoms in CR3 with heavy nitrogen amplifies the chemical shift of the amide proton to 
maximize the NMR signals of the peptide bond.  The spectrum collected for CR3 
residues 139-204 at 25 °C is shown in Figure 4-6.  The plot depicts the chemical shift of 
amide protons on the X-axis correlated to the chemical shift of the directly bonded amide 
nitrogen on the Y-axis.  The wide dispersion of NMR signals on the spectrum indicates 
residues that are in confined chemical environments, i.e., residues making intra-molecular 
contacts and potentially involved in protein folding.  Four peaks were shifted to the left of 
centre in regions of the spectrum usually reserved for tryptophan residues, i.e., between 
H1 of 10.1 to 9.1 ppm (Figure 4-6), yet there are no tryptophan residues in CR3.  
Although not conclusive, these dramatic chemical shifts suggest that these peaks 
correspond to the four coordinating cysteine residues that occupy this region, because the 
coordination of a single zinc ion presumably locks them in a rigid conformation.  
Unstructured residues that are flexible in solution fall to the centre of the 2D HSQC 
spectrum.  Clearly with full length CR3, there is substantial signal in this region that 
cannot be resolved, suggesting that a portion of CR3 is disordered and flexible in 
solution.  Moreover, there are resonant peaks found in this region that are characteristic 
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Figure 4-5 Purified CR3 Competes for MED23 Binding 
GST or GST-CR3 was mixed with 1 mg of A549 cell lysate and either buffer or increasing 
amounts of purified CR3.  Complexes were allowed to incubate at 4 °C for one hour with 
nutating and then recovered with glutathione sepharose.  Samples were then boiled in sample 
buffer, separated by SDS PAGE, transferred to membrane and subsequently immunoblotted for 
hMED23.  Immunoblot for hMED23 is shown above and Ponceau stain for GST and GST-CR3 
is shown below. 
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Figure 4-6  2D HSQC of CR3 Residues 139-204 
A 2D HSQC of purified 
15
N-labeled CR3 residues 139-204 was collected.  The Y axis 
depicts the 
15
N chemical shift and the X axis depicts the proton chemical shift.  Each 
peak represents an amino acid of CR3.  Red denotes resonant signals representing 
extremely flexible residues. 
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of glutamic acid residues (denoted in red Figure 4-6).    The resonant signal is most likely 
coming from the glutamic acid-proline (EP) repeats of AR-1, because this region was 
predicted by PONDR to be disordered (Figure 4-1).  Overall, initial NMR analysis of 
CR3 confirmed that at least a subdomain of CR3 has a well defined structure.  The 2D 
HSQC also indicates the presence of a disordered and flexible subdomain that 
complicates the resolution of the spectrum.  Therefore an alternative fragment of CR3 
was used for further experiments, with the aim of optimizing the spectrum for subsequent 
analysis.  
4.3.6 Construction and Analysis of CR3 Residues 139-190 
The spectrum obtained using residues 139-204 of hAd5 E1A CR3 lacked sufficient 
resolution to yield reliable structural information.  Therefore, I continued my experiments 
using a truncation of CR3 encompassing residues 139-190 of hAd5 E1A.  This particular 
truncation of CR3 was chosen based on a combination of practical and experimental 
considerations.  First and foremost, residue E189 was included based on previous data 
obtained from and E189A alanine substitution mutant of hAd5 E1A indicating that this 
residue is critical to CR3 transactivation as a Gal4DBD fusion (J. Ablack, unpublished 
data).  Evidence suggests that E189 may be involved in the tertiary structure of CR3.  
Residue P190 was included because together with E189 they reconstitutes the first EP 
repeat in AR1. Although it is not represented on the 2D HSQC due to a lack of an amide 
proton, as the terminal residue it can provide chemical shift information on the 
penultimate residue that could be involved in the structure of CR3.  The CR3 peptide 
fragment truncated at residue 190 was called CR3 190T.  CR3190T was purified by the 
procedure outlined above and a 2D HSQC was collected.  As predicted, the 2D HSQC of 
CR3 190T shows a dramatic increase in the resolution of individual peaks in the centre of 
spectrum (Figure 4-7).  The characteristic NMR signature of E1A CR3 was maintained in 
CR3190T, including the four characteristic peaks at the extreme left of the spectrum that 
are believed to be the coordinating cysteines (Figure 4-7).   
The literature indicates that the structure and function of CR3 is dependent on the 
coordination of a single zinc ion (10).  In order to test this possibility directly, I compared 
the 2D HSQC spectrum of CR3 190T in the absence and presence of the zinc chelator 
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Figure 4-7  2D HSQC of CR3 Residues 139-190 
A 2D HSQC of purified 
15
N-labeled CR3 190T (residues 139-190 of hAd5 E1A) was 
collected at 25°C.  The Y axis depicts the 
15
N chemical shift and the X axis depicts the 
proton chemical shift.  Each peak represents an amino acid of CR3 190T. 
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EDTA.  I first confirmed the spectrum of properly folded CR3 (Figure 4-8 black peaks).  
The sample was then treated with a five-fold molar excess of EDTA to chelate the zinc 
away from CR3 and the spectrum was recollected and overlaid on the spectrum prior to 
EDTA treatment (Figure 4-8 red peaks). The 2D HSQC of CR3 190T before treatment 
with EDTA is superimposable on the spectrum collected in Figure 4-7 (Figure 4-8 black 
peaks).  Upon treatment with excess EDTA, the peaks at the exterior of the CR3 190T 
spectrum collapsed into the centre, indicating a denatured and flexible structure (Figure 
4-8 red peaks).  This result conclusively demonstrates that the structure of E1A CR3 is 
dependent on zinc coordination.    Based on the EDTA zinc chelation experiment result, I 
sought to verify the 1:1 molar ratio of zinc ion binding previously reported by mass 
spectrometry, to ensure that the structure determined by NMR is dependent upon CR3 
binding a single zinc ion.  The 
15
N labeled sample of CR3 190T was analysed for mass 
determination by mass spectrometry under denaturing versus non-denaturing conditions.  
The predicted denatured mass of 
15
N labeled CR3 190T is 6480.59 Da and the denatured 
mass experimentally observed was 6480.24 Da (Figure 4-9).  Therefore, the denatured 
protein is present at the appropriate mass (2).  The mass spectrometry data also detected a 
smaller protein present in relative abundance with a mass of 5613.23 Da.  This 
corresponds to the first 48 residues of CR3190T, and indicates that most likely a 
proteolytic cleavage occurs after residue 48 of CR3190T in some of the purified material 
(Figure 4-9).  As expected, both of these peptides showed an increase in mass under non-
denaturing conditions of approximately 63 Da, which is the mass of a single zinc ion.  
Therefore both CR3 fragments observed, residues 139-190 and residues 139-182 of hAd5 
E1A, are capable of binding a single zinc ion, in agreement with what has been published 
previously (10).  The discovery of the truncated species in the purified CR3 was of 
concern, since the ratio of the two species was unknown, and the presence of two species 
would complicate analysis of the NMR data.  Since both species could clearly still 
coordinate a single zinc ion, we decided to truncate CR3 to the smaller fragment in order 
to obtain a homogeneous population of purified protein.  As mentioned above, the mass 
of the smaller species indicated it terminates at residue F182 of hAd5 E1A (2).   
Examination of the primary amino acid sequence of CR3 shows that residue 179 is the 
sole cysteine in CR3 that is not involved in zinc coordination (10).  However, this 
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Figure 4-8  2D HSQC of CR3 190T With and Without EDTA 
A 2D HSQC of purified 
15
N-labeled CR3 190T (residues 139-190 of hAd5 E1A) was 
collected at 25°C.  The Y-axis depicts the 
15
N chemical shift and the X-axis depicts the 
proton chemical shift.  Each peak represents an amino acid of CR3. Black peaks are the 
spectrum of CR3 190T collected in the absence of EDTA.  Red peaks are the spectrum 
of CR3 190T collected after the addition of 500 mM EDTA. 
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Figure 4-9 Mass Determination of CR3 190T with and without Zinc 
Purified CR3 190T (residues 139-190 of hAd5 E1A) was analyzed by ESI QTOF mass 
spectrometry.  The predicted denatured mass of 
15
N labeled CR3 190T is 6480.59 Da.  
TOP:  Under denaturing conditions (50% acetonitrile) two predominant species of CR3 
were observed with masses of 5613.23 Da and 6480.24 Da corresponding to residues 
139-182 and 139-190 of hAd5 E1A CR3, respectively.  BOTTOM:  Under non-
denaturing conditions (10 mM ammonium acetate) the mass of both species has 
increased by 63 Da, which is the mass of one zinc ion. 
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cysteine could still form disulfide bonds, further complicating purification and 
interpretation of the NMR spectrum.  Therefore I have truncated CR3 at residue 178 to 
remove this cysteine for all subsequent experiments.  This was done by truncating the 
CR3 domain of hAd5 E1A by PCR and recloning the new fragment into pGEX4T1-TEV; 
the new construct was designated CR3178T.  However, CR3178T has not been used in 
any of the experiments described in this thesis.  Future experiments involving CR3178T 
are discussed in chapter 5. 
 CR3190T was also subjected to circular dichroism (CD) spectropolarimetry to confirm 
the overall structured nature of E1A CR3 and gain insight into potential secondary 
structure of E1A CR3.  A CD spectrum of the purified CR3 190T sample was collected at 
25 °C and is shown in Figure 4-10A (blue curve).  CR3 190T showed bands of ellipticity 
whose minima were between 208 nm and 222 nm, and also some positive character 
below 200 nm.  The spectrum is strongly indicative of a structured protein.  However, it 
is not consistent with an entirely α-helical or β-sheet protein, but rather likely contains a 
combination of both types of structures.    Further insight into the stability of CR3190T 
was gained by measuring mean residue ellipticity (MRE/[θ]) at 222 nm over a 
temperature range.  The MRE of CR3190T at 222 nm decreased sharply at approximately 
70 °C, which indicated that the structure of CR3 unfolded upon heat denaturation (Figure 
4-10B).  The sample of CR3190T was allowed to cool back to 25 °C and the CD 
spectrum was recollected.  After heat denaturation, the CD spectrum was nearly 
superimposable on the spectrum collected before heat denaturation (Figure 4-10A red 
curve).  Upon cooling, presumably in the presence of zinc ions, CR3190T was apparently 
able to refold in a self-directed manner. 
4.4 Discussion 
Overall, we demonstrated conclusively that CR3 contains a zinc-dependent structured 
subdomain and have mapped the boundaries of the zinc binding subdomain of CR3 to 
include up to residue 182 of hAd5 E1A.  Moreover, we have confirmed previous reports 
that E1A CR3 binds a single zinc ion and is capable of self-directed refolding (10, 20, 
25).  Also my analysis of the purified fragments of CR3 indicates that our material is 
properly folded and still capable of interacting with key cellular targets of E1A CR3. 
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Figure 4-10: Far UV CD Spectra of CR3190T 
A 
B 
 A) Far UV CD spectra for CR3190T (residues 139-190 of hAd5 E1A) was 
collected at 25°C in 10 mM PO4 buffer pH 6.5 at a concentration of 100 µM (blue 
spectrum).  The same sample was denatured by heating (see B), cooled to room 
temperature and the CD spectrum was recollected at 25 °C (Red spectrum, post 
MC).  B) Melting curve of CR3190T.  The MRE ([θ]) was monitored at 222 nm as 
CR3190T was heated to 100°C. 
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The bioinformatic tool PONDR predicted two major regions of order in hAd5 E1A.  
Peaks of order corresponded to the extreme N-terminus and CR3 of hAd5 E1A (Figure 4-
1).  The region in the N-terminus of hAd5 E1A predicted by PONDR is thought to fold 
into an amphipathic alpha helix which is critical to the proper organization of the 15 
cellular proteins known to interact with this region (30).  Furthermore, this amphipathic 
alpha helix that is predicted to be conserved among representative members of each hAd 
species (30).  As demonstrated above, the prediction of an ordered domain in CR3 of 
hAd5 E1A has now been verified experimentally by NMR spectroscopy (Figures 4-6 to 
4-8).   
PONDR also predicted multiple regions of intrinsic disorder within CR1 and CR2 of 
hAd5 E1A (Figure 4-1).  Intrinsic disorder refers to a region of a protein that samples a 
wide range of conformational space in solution and only takes on a fixed structure when 
bound to its appropriate partners.  The true disordered nature of CR1 and CR2 of hAd5 
E1A were recently demonstrated experimentally.    The solution structure of hAd5 E1A 
CR1 and CR2 in complex with the TAZ2 domain of CBP and the pocket domain pRb has 
been solved (13).  The structure shows E1A binding to the TAZ2 domain of CBP and the 
pocket domain of pRb, through CR1 and CR2, respectively, and independently of each 
other.  There is also an interaction site for pRb in CR1 of E1A that is independent of the 
TAZ2 interaction site (27).   The solution structure also reveals that CR1 and CR2 of 
E1A take on a helical structure upon interaction with these binding partners (13).  My 
PONDR prediction showed three peaks of intrinsic disorder in regions of E1A that 
correspond to the interaction sites of TAZ2 and pRb.  Each PONDR predicted disordered 
peak was thus validated experimentally by the work of Ferreon et al. (13) as an 
intrinsically disordered region of E1A critical to the interaction with E1A‘s cellular 
partners and essential to E1A performing one of its central functions, uncoupling cell 
cycle regulation.  Therefore overall, PONDR has successfully predicted the landscape of 
order versus disorder in hAd5 E1A. 
The initial NMR experiments using residues 139-204 of hAd5 E1A that includes CR3 
and AR1 indicated that this peptide was both structured and unstructured (Figure 4-6).  
PONDR also predicted that residues 139-204 contained both structured and disordered 
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regions (Figure 4-1). The dichotomy of the NMR spectrum for CR3/AR1 is not entirely 
unexpected, since the literature has suggested that CR3 consists of two functional 
subdomains; a structured zinc finger subdomain and a disordered promoter targeting 
subdomain.  These two subdomains are thought to cooperate in order to activate 
transcription of the early viral promoters.  The zinc finger subdomain makes specific 
contact with key cellular transcription factors such as TBP and MED23, thus recruiting 
the cellular transcription machinery (6).  Meanwhile, the promoter-targeting subdomain 
of E1A CR3 can make promiscuous interactions with sequence-specific DNA-binding 
transcription factors, locating E1A and transcription machinery to the diverse viral 
promoters (26, 28). 
The requirement for zinc in E1A CR3 transactivation has been studied in detail.  Single 
point mutations in any of the coordinating cysteine residues abrogate transactivation by 
full length E1A on an E4 promoter and also by CR3 when fused to the Gal4DBD (3, 18).  
Furthermore, conversion of the C4 zinc finger domain of CR3 to a C2H2 zinc finger also 
abrogates E1A transactivation (40).  My mass spectrometry analysis of CR3 190T 
demonstrated that the zinc finger subdomain of E1A CR3 binds a single zinc ion, 
consistent with a previous report that showed E1A CR3 bound a single zinc ion by X-ray 
ion absorption spectroscopy (10).  The function of E1A CR3 has already been shown to 
depend on the coordination of a single zinc ion and my data now demonstrate that there is 
a correlation between the 3D structure of E1A CR3, coordination of single zinc ion, and 
transactivation (10, 17, 40). 
CD spectropolarimetry demonstrated that residues 139-190 of hAd5 E1A contain both α-
helical and β-sheet secondary structures (Figure 4-10).  The amino acid sequence of E1A 
CR3 may also hold some insight into possible secondary structure of this region.  Proline 
residues are unable to form α-helix or β-sheet secondary structures, due to a lack of 
amide protons to form hydrogen bonds, and pralines would therefore not be found 
concentrated in regions of secondary structure  (38).  hAd5 289R E1A contains a total of 
46 (15.86%) prolines.  Between residues 139-204 within CR3 of hAd5 E1A there are 10 
prolines (15.15%), indicating that CR3 has roughly the same proportion of prolines as the 
rest of E1A (ref protein calculator).  However the distribution of proline residues within 
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CR3 is very uneven.  Of the 10 prolines, 8 are found within the promoter-targeting 
subdomain/AR1, which our NMR analysis suggests is part of unstructured region at the 
C-terminus of CR3 (Figure 4-6).  The remaining two prolines are found at precisely 4 
residues upstream of the CXXC zinc binding motifs in the zinc finger subdomain, which 
may indicate that these two prolines are involved in segregating secondary structures 
associated with zinc coordination.  Mutation of P150 (4 residues upstream of the first 
CXXC motif) to glycine results in complete loss of CR3 function, while mutation of 
P167 to glycine appears to have no effect, suggesting that the proline upstream of the first 
CXXC motif is more important for the folding and structure of CR3 (17, 40).  The zinc-
binding region of Human papillomavirus E7, another early protein from a small DNA 
tumor virus that activates transcription, has been crystallized and its structure includes 
both α-helical and β-sheet secondary structure and bears no homology to other known 
zinc-binding proteins (27).  Perhaps the hAd E1A CR3 zinc binding region, which also 
bears no homology to known zinc binding proteins, is adopting a similar blend of 
secondary structures to properly organize its cellular binding partners to initiate 
transcription.   
Curiously, upon refolding of the CR3190T peptide that had been heated to 100 °C, the 
quality of the signal at the lowest wavelengths improved.  I speculate this may be the 
result of contaminating proteins that were absorbing polarized light before denaturing 
that were unable to refold after cooling.  Thus, the absence of contaminating signal would 
then allow E1A CR3 to become more prominent in this region of the spectrum. These 
observations are consistent with self-directed folding of E1A CR3 that has been 
demonstrated previously.  Specifically, microinjection of a peptide corresponding to 
residues 140-188 of E1A CR3 could activate transcription of an adenoviral E2 promoter 
even after heating to 100 °C (20, 25). 
The structure determination of the zinc finger subdomain of E1A CR3 is ongoing, using 
E1A-CR3 residues 139-178.   The ultimate goal of this project is a high resolution 
structural model of the ordered zinc finger subdomain of hAd5 E1A CR3.  The structural 
insight into CR3 function is essential to a complete model of E1A CR3 transactivation 
which serves as a paradigm for non-acidic viral transactivators. 
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Chapter 5  
5 General Discussion & Future Directions 
This body of work describes recent advances in the current understanding of a critical 
function of hAd E1A—activating transcription of the early viral promoters.  This 
function of E1A ‗kickstarts‘ the viral replication cycle by supplying the early viral 
mRNAs whose translated products are required for hijacking cellular machinery, 
preventing antiviral defenses, blocking the host immune response and synthesizing the 
viral genome (22).  The model by which E1A activates transcription of the early viral 
promoters is that E1A interacts with key cellular proteins and relocates a functional 
transcription preinitiation complex to the viral template.  Within these chapters the model 
for E1A-CR3 function has been tested, refined and expanded, ultimately furthering our 
understanding of this paradigm of non-acidic viral transactivators.  
5.1 Thesis Summary 
The existing model for E1A-CR3 was developed almost exclusively with hAd5 E1A-
CR3 of species C, as a prototype for the greater than 51 other types that fall into five 
additional species (1, 22).  Based on the tissue tropism and diverse growth characteristics 
of the hAd family as a whole, I set out to expand this model to include a representative 
member of each hAd species and to integrate the function of new cellular factors that 
have been implicated in E1A transactivation in recent years (3, 18-20).  In Chapter 2, I 
systematically tested the pre-existing model of E1A-CR3 transactivation with a 
representative E1A-CR3 from each hAd species and demonstrated that the co-activators 
of E1A-CR3 were conserved across the hAd family, despite dramatic differences in the 
abilities of the individual CR3s to activate transcription.  This work also indicated that 
additional cellular factors are likely required by E1A-CR3 to activate transcription.   
In Chapter 3, I described the role of a novel negative regulator of E1A-CR3 
transactivation, the KAT GCN5.  I identified a second interaction surface for GCN5 that 
mapped to residues 178-184 of E1A, which resides within CR3.  I also showed that 
GCN5 was only recruited to the E4 promoter when both binding sites in E1A were 
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present, conclusively demonstrating that cooperative binding of a factor by the N-
terminus and CR3 of E1A was essential for activation.  I also established that the KAT 
activity of GCN5 had a negative regulatory effect on E1A transactivation and that this 
was required for optimal virus growth.  The KAT activity of GCN5 may possibly 
regulate phosphorylation of S188 in E1A-CR3, which is known to be critical for 
activation of the viral E4 promoter.  The E4 transcription unit contains some of the most 
toxic viral proteins in hAd genome, and tight control of their expression may be essential 
in order to maximize virus yield (27).  This work provides a glimpse into the levels of 
control that are coordinated by E1A CR3 to provide the optimal level of early gene 
expression and suggests that overexpression of at least some early viral genes may be 
detrimental to virus growth.   
Finally, despite anecdotal evidence that a complex secondary and tertiary structure is 
paramount to the function of E1A-CR3, there was no experimental evidence that E1A 
CR3 is structured.  In chapter 4, my experimental analysis of E1A-CR3 structure by 
NMR and CD spectropolarimetry revealed that E1A-CR3 is composed of both a 
structured subdomain and a disordered subdomain. This analysis correlates with the 
existing functional data regarding E1A CR3-mediated transcriptional activation.  
Specifically, the structured zinc finger subdomain has been implicated as critical to 
recruiting the cellular transcription factors necessary to stimulate transcription, while the 
disordered subdomain has traditionally been associated with dominant negative mutants 
and known to be essential for targeting E1A to the viral promoters (2, 9, 13, 14, 26).  The 
rigid structure of the zinc finger subdomain of E1A CR3 is dependent upon coordination 
of a single zinc ion, thereby providing a structural basis for the functional requirement of 
zinc in E1A transactivation (6, 9, 25).  The disordered nature of the C-terminal 
subdomain of E1A CR3 may be the key to the broad ability of E1A to activate 
transcription from multiple cellular promoters via promiscuous interactions with 
numerous cellular transcription factors (15). I have also confirmed the self-directed 
nature of the zinc finger subdomain folding by CD spectropolarimetry.  The results of 
this analysis were consistent with reports indicating that the presence of zinc is the most 
critical factor in E1A CR3 folding (Figure 4-8, Figure 4-10) (6, 10). The structure of E1A 
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CR3 will add a great deal of insight as to how this compact viral domain functions as a 
potent activator of transcription.   
Overall, the work completed here expands our knowledge of E1A function and is the 
beginning of a highly detailed mechanism for E1A transactivation.  Our refined model 
includes a layer of negative autoregulation and structural insight into the paradigm of 
E1A transactivation.  
5.2 The Co-Activators of E1A CR3 are Conserved 
Across All Six hAd Speciess 
One of the main goals of this research project was to expand our knowledge of E1A-CR3 
transactivation with respect to the hAd family as a whole.  To this end, I directly 
compared the ability of E1A CR3s from representative members of each hAd species to 
activate transcription as Gal4DBD fusions and examined the role of each known cellular 
co-activator of E1A CR3 in this process.  Together, this work not only demonstrated that 
there are dramatic differences in the magnitude of each E1A CR3‘s ability to activate 
transcription, but also showed that the known co-activators of E1A CR3 were not at the 
heart of these differences in activity.  Furthermore, while validating our squelching assay 
for CR3 transactivation using well defined mutants of CR3, it became apparent that 
additional potentially rate-limiting cellular factors could be involved in the process of 
transcriptional activation.  Taken together these observations suggest that there could not 
only be additional cellular factors at work, but these factors could possibly be hAd type-
specific, thus tuning the transcriptional output of E1A to suit each hAd‘s niche.  To 
complete our understanding of this process, all of the players involved need to be 
identified.   
One approach to identifying new cellular factors required by hAd5 E1A CR3 to activate 
transcription has been undertaken byDr. Mymryk‘s laboratory in collaboration with 
Charles Boone at the Banting and Best Institute at the University of Toronto.  This 
project involves using the power of yeast genetics to systematically screen for all of the 
cellular factors required by hAd5 E1A CR3 to activate transcription.  A similar small 
scale screen of this type has already been completed by my colleagues in Dr. Mymryk‘s 
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laboratory (29).  E1A‘s history of targeting highly conserved factors to activate 
transcription make this sort of screen possible, since it is known that E1A CR3 is an 
effective transactivator in yeast (18, 23, 29).  The purpose of these screens is to identify 
new genes required by E1A to activate transcription in yeast and then examine the role 
played by their mammalian orthologues in E1A-transactivation.  The simplicity and tools 
available in the yeast system make this a very attractive approach.  However, these 
screens do not look at E1A transactivation of the viral genome directly, and many cellular 
genes do not have yeast orthologues.    
To address some of the issues raised above, I would approach the problem from an 
entirely different perspective and directly compare cellular factors required for E1A-
dependent transactivation of early viral genes.  Initial experiments revealed that 
incompatibilities between hAd promoter sequences of one type and the E1A proteins of 
other types precluded direct comparison of representative E1As on the same promoter 
(Ablack unpublished). Therefore, in order to make direct comparisons, it was imperative 
to compare CR3 function and the role of cellular factors using GalDBD fusions to CR3 
fragments.  Later, I was eventually able to develop an assay which directly compares 
E1A transactivation among hAds by qRT-PCR and measures relative expression of the 
E4ORF6/7 gene from the E4 promoter during infection (Figure 2-8B).  Using this assay, 
the ability of each E1A to activate its own E4 promoter could be compared in the absence 
of suspected or implicated cellular transcription factors.   
Unfortunately, using RNAi to deplete cellular targets in the context of infection can 
become problematic, because hAd encodes two virus associated RNAs (VA RNAs) that 
have been reported to occupy 80% of cellular RISC complexes during infection, 
effectively blocking the RNAi machinery (28).  However, provided the target cellular 
mRNAs were knocked down prior to infection, the requirement for that particular cellular 
factor in initiating transcription of the E4 promoter could theoretically be examined.  My 
high throughput qRT-PCR assay for E4 promoter activity could be combined with a large 
scale siRNA library screen for cellular transcription factors in order to identify genes 
required by specific hAd species to activate transcription.  I propose initially comparing 
the prototype hAd5 to hAd9, because the CR3 region of hAd9 is the most divergent, and 
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clearly the weakest activator, yet hAd9 full length E1A is a potent activator in the context 
of infection (Figure 2-1, Figure 2-8).  Genes identified as functionally required by E1A to 
activate transcription from the screen could easily be validated against the entire panel of 
representative hAds.   
Based on my observations from Chapter 3, there is clearly a role for cellular factors, such 
as GCN5, to negatively regulate E1A transactivation.  The unbiased nature of the 
E4ORF6/7 qRT-PCR assay allows to us screen both for factors that decrease or increase 
E1A transactivation.  The limitations to these sorts of experiments lie in the lack of 
reagents for non-hAd5 viruses.  With the exception of hAd12, mutants even simply 
lacking E1A are not generally available. Thus, the screen would compare the relative 
expression level of E4ORF6/7 in cells infected with wt hAd from any species A-F treated 
with either control siRNA or targeting siRNA.  Furthermore, the means to make 
recombinant non-Ad5 viruses is also unavailable for representative members of each hAd 
species, hindering screening based on viral reporter systems.  At the moment, qRT-PCR 
of early viral genes such as E4ORF6/7 is the most feasible means to make direct 
functional comparisons of E1A transactivation among representative hAds. This screen 
would still be highly relevant to the events occurring early during infection, because E1A 
is the first viral gene expressed.  
Alternatively, a complementary biochemical screen for novel binding partners could be 
utilized to decipher the differences among representative E1A CR3s.  It would require 
construction of stable cell lines expressing distinctly tagged 12S and 13S E1As from each 
human hAd species, i.e. Flag-tagged 12S E1A and HA-tagged 13S E1A.  Cell lines 
would be generated using A549 cells, because this cell line supports growth of all hAds, 
and we would employ cDNA clones for these tagged E1As that are currently available in 
our lab.  The interacting partners of the E1A CR3s of each hAd species could then be 
determined by comparative proteomic analysis using the Comparative Proteomic 
Analysis Software Suite (CompPASS).  The elegance of this approach is that it generates 
high confidence interacting proteins (HCIPs) based on the frequency of a given peptide 
identified by mass spectrometry among replicate samples, and it subtracts non-specific 
peptides found in a control sample where no test protein is present (i.e., from cell lines 
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harboring empty HA or Flag expression vectors) (24).  Therefore, mass spectrometry-
based proteomic analysis on HA-IPs would establish the binding partners for 13S E1A 
after subtracting out binding partners identified in both control IPs and Flag-IPs for the 
respective 12S E1A.  In this way, HCIPs specific to the CR3 region could be determined 
for each hAd E1A.  The role of cellular binding partners identified by CompPASS could 
then be directly tested using RNAi and the qRT-PCR assay for E4ORF6/7 described 
above.   
The work presented in chapter 3 also demonstrates cooperative binding of cellular targets 
by the N-terminus and CR3 of E1A.  The pliability of the CompPASS approach allows 
examination and identification of common and/or cooperative interactions between the 
N-terminus and CR3 of any E1A.  Proteomic data could also be mined by subtracting the 
control IPs and looking for peptides common to both E1A isoforms, but enriched in the 
HA-IPs for 13S E1A, to identify factors that interact cooperatively with both regions.  
Since E1A peptides will be present in the IPs, the frequency of peptides enriched by 13S 
E1A could be normalized to the frequency of E1A peptides found as a relative level of 
E1A expression.  There are already several cellular factors that have binding sites in both 
the N-terminus of E1A and CR3 that could serve to validate this approach, including 
p300/CBP, pCAF, TBP and GCN5 (Figure 3-2) (13, 18, 19). 
Together these approaches could exhaustively search for and identify all of the cellular 
factors required by E1A-CR3 to activate transcription of human adenoviral promoters in 
the context of infection.  Although a challenging and a large undertaking, the tools to 
execute these experiments are currently available in our lab and could be carried with the 
appropriate collaborations.  Using these approaches to identify all of the players involved, 
a complete and inclusive model for E1A-transactivation across the entire hAd family 
could be elucidated. 
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5.3 The KAT-GCN5 is a Novel Negative Regulator of 
E1A Dependent Transactivation 
In Chapter 3, the KAT GCN5 was identified as a novel negative regulator of E1A CR3-
dependent transactivation.  GCN5 was recruited to the E4 promoter, and RNAi depletion, 
mutation of the catalytic site of GCN5, or pharmacological inhibition of KAT activity 
resulted in an increase in transactivation by E1A CR3 and full length E1A.  Thus, the 
KAT activity was necessary to exert the negative effect on E1A CR3.  However, a 
precise mechanism as to how this occurs is not clear.  Close examination of the literature 
revealed a possible link to GCN5 and E1A-transactivation that involved the mediator 
sub-complex T/G Mediator (composed of Mediator subunits including MED23, GCN5 
and CDK8).  T/G Mediator is required for tandem phosphoacetylation of S10/K14 on H3 
(16).  All three of these components can be linked to E1A; MED23 and CDK8 co-purify 
with E1A-CR3 (2), and I have shown here that E1A-CR3 is sufficient for GCN5 
interaction (Figure 3-1B).  Furthermore, I identified a potential consensus CDK8 
phosphorylation site spanning residues 184-188 (YSPVS) of hAd5 CR3, where the 
terminal S (S188 in E1A) is phosphorylated.  This sequence is highly conserved in our 
panel of representative E1A CR3s (species F hAds have the sequence YSPIS).  
Therefore, since all three key players are interacting with E1A via CR3, and the kinase 
responsible for S188 phosphorylation has yet to be identified, this complex could be 
responsible for E1A S188 phosphorylation, a modification known to affect E4 
transactivation (16, 21, 27).  To determine the role of T/G Mediator in E1A 
transactivation, I would first look at the properties of E1A harboring a single point 
mutation at S188 to alanine, as well as a mutant that loses interaction with MED23, such 
as H160Y (Boyer 1999, (2, 9). Then, using the assays presented in Chapter 3, I would 
determine if these mutants could interact with GCN5 and were no longer responsive to 
RNAi depletion, overexpression, and pharmacological inhibition of GCN5.  These 
mutants could also be used in kinase assays to determine if S188 was phosphorylated in a 
manner consistent with GCN5 and MED23 binding.  This series of experiments could 
link phosphorylation of S188 to the Mediator complex and the effect of GCN5.  Next, I 
would test whether CDK8 is the kinase responsible for S188 phosphorylation in two 
ways: 1) I would look for an interaction between CDK8 and wt E1A CR3 by Co-IP.  I 
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could then attempt to correlate CDK8 binding to Mediator and GCN5 binding using CR3 
mutants that lose interaction with Mediator and GCN5 (the H160Y mutant and Δ178-184 
E1A mutants, respectively) by co-IP.    The invariant Y residue of the YSPVS sequence 
in E1A CR3 corresponds to Y184, which when deleted along with residues 178-183, 
results in a loss of GCN5 interaction.  I will also mutate this residue and examine the 
effect on GCN5 binding and E1A transactivation.  2) The role of CDK8 in E1A CR3 
transactivation will be tested directly by RNAi depletion of CDK8 and pharmacological 
inhibition of its kinase activity using the same assays described in Chapter 3.     
Our working model is that the KAT activity of GCN5 regulates CDK8, which in turn 
phosphorylates S188 on E1A, which is the most transcriptionally active form of E1A 
CR3 (27).  I suspect that the explanation for repression of E1A-dependent transactivation 
by GCN5 overexpression is due to the generation of a hypophosphorylated form of E1A 
at S188. Conversely, knocking-down GCN5 or pharmacologically inhibiting/mutating the 
KAT of GCN5 indirectly results in hyperphosphorylated E1A CR3 at S188.  How the 
KAT transferase activity is potentially regulating CDK8 would also need to be 
determined.  There is growing evidence that non-histone proteins are acetylated and that 
this reversible post-translation modification is involved in many cellular processes, 
including regulating kinases (4).  In fact, members of the GCN5-containing STAGA 
complex (SAGA in yeast) have been shown to be acetylated by GCN5 (4, 8, 17).  Once 
the players involved are determined by the experiments described above, the role for 
acetylation and which components are acetylated could be determined. 
In 2008, the total promoter occupancy of hAd5 243R E1A was shown to result in a global 
hypoacetylation of histone H3 Lysine 18 (H3K18), an epigenetic mark generally 
associated with transcriptional repression.  Indeed, 12S E1A was shown to occupy greater 
than 70% of cellular promoters and completely redistribute p300 and pRb promoter 
occupancy (12).  However, very little is known about the 13S E1A product in terms of 
activating cellular genes during the course of infection.  Given that the 13S E1A product 
has all of the regions in the 12S product and an additional transactivation/promoter 
targeting domain, it stands to reason that the 13S product could also occupy cellular 
promoters.  Recent evidence indicating that 13S E1A can use repressors such as CtBP to 
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activate silenced promoters implies that CR3 could be contributing to global changes in 
cellular gene expression (3).  Based on the shocking global changes in cellular promoter 
occupancy mediated by 12S E1A (7, 12), the global promoter occupancy of 13S E1A is 
of great interest to the field.  Using chromatin immunoprecipitation-deep sequencing 
(ChIP-Seq) the promoter occupancy of 13S E1A could be determined and compared to 
that of 12S E1A.  There is a monoclonal E1A antibody that specifically 
immunoprecipitates the 13S E1A of hAd5 (11).  Using this monoclonal antibody, the 
promoter occupancy of 13S E1A in context of infection and in the presence of 12S E1A 
could be determined.  Comprehensive analysis of 12S and 13S E1A function on cellular 
promoters would provide critical insight to the roles played by each of these two very 
similar proteins that are both present in abundance at early times during infection.   
5.4 The Structure of hAd5 E1A CR3 
My progress, in concert with others, in determining the structure of E1A-CR3 is close to 
yielding a high resolution model.  The key to resolving a structure by NMR is the 
collection of lots of data and satisfying as many experimental and theoretical constraints 
as possible in order to compute the high resolution final structure.  First and foremost, 
each amino acid of the protein backbone must be assigned chemical shifts by 3D labeling 
techniques in order to track individual amino acids in subsequent experiments.  For this 
to be completed, E1A CR3 178T will be overexpressed in E. coli strain DE3 plysys, with 
15
N ammonium chloride and 
13
C glucose as the only nitrogen and carbon sources 
respectively, to isotopically label the protein.  Once double labeled recombinant protein 
of sufficient quality and quantity is prepared, a series of 3D HSQC experiments can be 
performed to generate sufficient data such that with the appropriate computation it will be 
possible to assign each peak to an amino acid in the E1A CR3 sequence.  When the 
protein backbone is assigned, chemical shifts of each aa will provide insight into any 
secondary structure.  In general, α-helices will cause upfield shifts in 1Hα and 13Cβ and 
downfield shift, in 
13Cα 13C‘, while β-sheets have the opposite effect: downfield shifts in 
1Hα and 13Cβ and upfield shifts in 13Cα 13C‘.  This chemical shift data can be input into 
programs such as TALOS (Torsion Angle Likelihood Obtained from Shift and sequence 
similarity) (5) to determined phi, and psi angles of the protein backbone.  In order to 
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determine the tertiary structure of proteins by NMR, it will be necessary to take 
advantage of the nuclear overhauser effect (NOE).  The NOE states that protons within 
5Å of each other will interact and generate cross peaks in a NOESY experiment. 
Therefore, the amide protons of E1A CR3 that are in close proximity in space but 
separated in the primary amino acid sequence can be identified.  The cross peaks of the 
NOESY experiment are included in the constraints input into software packages that 
determine conformers of the aa sequence that fit all of the constraints.  The quality of the 
NMR structure is dependent upon the number of experimental constraints and the 
flexibility of the protein.  In the case of E1A CR3, we are trying to assign only 48 amino 
acids, which based on our data and predictions thus far, appear to be quite rigid in nature.  
These properties of E1A CR3 make it a very likely candidate for a solvable solution 
structure.  The ultimate goal of this project is a 3D model of E1A CR3 structure. 
Once the structure is available, it will be necessary to test the vast collection of mutants 
available in CR3 to validate the structure.  I will begin by looking at the group I hr 
mutants, which are known to have biological consequences, and determine if any of these 
mutants are required for structural stability.  Furthermore, one can make strategic 
mutations in CR3 to disrupt key intra-molecular contacts and assay their phenotype by 
the Gal4DBD transactivation assays described in Chapter 2.  Ultimately, fine mapping 
the contribution of solvent-exposed residues to interaction surfaces on E1A CR3 with the 
known cellular binding partners, such as MED23, will also be performed using strategic 
mutations or existing published data.  These mutants can also be used in vitro to 
catalogue cellular factors that bind directly to E1A CR3 and those that interact with E1A 
through large multi-protein complexes.  Adding this level of detail to the model of E1A 
CR3 transactivation will allow for a complete and validated paradigm of E1A CR3 
function. 
5.5 Concluding Remarks 
Viruses are obligate intracellular parasites.  The study of viruses including small DNA 
tumor viruses such as hAd, serves two purposes. Firstly, since many viruses cause 
disease, it is useful to understand the mechanisms of viral pathogenesis in order to 
effectively combat these pathogens.  Secondly, the complex co-evolution of host and 
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pathogen can be viewed as a molecular arms race.  The tremendous selective pressure 
exerted on viruses by the host selects for innovation at the molecular level.  Thus, viruses 
can function as discriminating biochemical tools to probe important host pathways.  It is 
in this way that the E1A protein has truly been of value, and studies of this versatile viral 
protein have propelled our understanding of many cellular processes and will likely 
continue to do so for many years to come. 
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